<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2023.1102486</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>IL-17A expression by both T cells and non-T cells contribute to HSV-IL-2-induced CNS demyelination</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Hirose</surname>
<given-names>Satoshi</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Shaohui</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1380308"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jaggi</surname>
<given-names>Ujjaldeep</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2031778"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Matundan</surname>
<given-names>Harry H.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kato</surname>
<given-names>Mihoko</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Song</surname>
<given-names>Xue-Ying</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Molesworth-Kenyon</surname>
<given-names>Sara J.</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lausch</surname>
<given-names>Robert N.</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Ghiasi</surname>
<given-names>Homayon</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/339418"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Center for Neurobiology &amp; Vaccine Development, Ophthalmology Research, Department of Surgery, Cedars-Sinai Medical Center</institution>, <addr-line>Los Angeles, CA</addr-line>, <country>United States</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Biology, Pomona College</institution>, <addr-line>Claremont, CA</addr-line>, <country>United States</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Applied Genomics, Computation, and Translational Core, Cedars-Sinai Medical Center</institution>, <addr-line>Los Angeles, CA</addr-line>, <country>United States</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Department of Natural Sciences, University of West Georgia</institution>, <addr-line>Carrollton, GA</addr-line>, <country>United States</country>
</aff>
<aff id="aff5">
<sup>5</sup>
<institution>Department of Microbiology and Immunology, University of South Alabama, College of Medicine</institution>, <addr-line>Mobile, Al</addr-line>, <country>United States</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Richard D. Dix, Georgia State University, United States</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Clinton Jones, Oklahoma State University, United States; Tibor Valyi-Nagy, University of Illinois at Chicago, United States</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Homayon Ghiasi, <email xlink:href="mailto:ghiasih@CSHS.org">ghiasih@CSHS.org</email>
</p>
</fn>
<fn fn-type="other" id="fn002">
<p>This article was submitted to Viral Immunology, a section of the journal Frontiers in Immunology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>02</day>
<month>02</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>14</volume>
<elocation-id>1102486</elocation-id>
<history>
<date date-type="received">
<day>18</day>
<month>11</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>20</day>
<month>01</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2023 Hirose, Wang, Jaggi, Matundan, Kato, Song, Molesworth-Kenyon, Lausch and Ghiasi</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Hirose, Wang, Jaggi, Matundan, Kato, Song, Molesworth-Kenyon, Lausch and Ghiasi</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Previously we reported that a recombinant HSV-1 expressing murine IL-2 (HSV-IL-2) causes CNS demyelination in different strains of mice and in a T cell-dependent manner. Since T<sub>H</sub>17 cells have been implicated in CNS pathology, in the present study, we looked into the effects of IL-17A<sup>-/-</sup> and three of its receptors on HSV-IL-2-induced CNS demyelination. IL-17A<sup>-/-</sup> mice did not develop CNS demyelination, while IL-17RA<sup>-/-</sup>, IL-17RC<sup>-/-</sup>, IL-17RD<sup>-/-</sup> and IL-17RA<sup>-/-</sup>RC<sup>-/-</sup> mice developed CNS demyelination. Adoptive transfer of T cells from wild-type (WT) mice to IL-17A<sup>-/-</sup> mice or T cells from IL-17A<sup>-/-</sup> mice to Rag<sup>-/-</sup> mice induced CNS demyelination in infected mice. Adoptive T cell experiments suggest that both T cells and non-T cells expressing IL-17A contribute to HSV-IL-2-induced CNS demyelination with no difference in the severity of demyelination between the two groups of IL-17A producing cells. IL-6, IL-10, or TGF&#x3b2; did not contribute to CNS demyelination in infected mice. Transcriptome analysis between IL-17A<sup>-/-</sup> brain and spinal cord of infected mice with and without T cell transfer from WT mice revealed that &#x201c;neuron projection extension involved in neuron projection guidance&#x201d; and &#x201c;ensheathment of neurons&#x201d; pathways were associated with CNS demyelination. Collectively, the results indicate the importance of IL-17A in CNS demyelination and the possible involvement of more than three of IL-17 receptors in CNS demyelination.</p>
</abstract>
<kwd-group>
<kwd>Ocular infection</kwd>
<kwd>mouse</kwd>
<kwd>HSV-IL-2</kwd>
<kwd>knockout</kwd>
<kwd>IL17RA</kwd>
<kwd>IL17RC</kwd>
<kwd>IL17RD</kwd>
</kwd-group>
<contract-num rid="cn001">RO1EY029677 ,  RO1EY13615,  RO1EY26944.</contract-num>
<contract-sponsor id="cn001">National Eye Institute<named-content content-type="fundref-id">10.13039/100000053</named-content>
</contract-sponsor>
<counts>
<fig-count count="10"/>
<table-count count="2"/>
<equation-count count="0"/>
<ref-count count="111"/>
<page-count count="15"/>
<word-count count="8528"/>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Optic neuritis involves primary inflammation of the optic nerve and is associated with loss of vision or double vision, and painful ocular movements (<xref ref-type="bibr" rid="B1">1</xref>&#x2013;<xref ref-type="bibr" rid="B3">3</xref>). Several lines of evidence indicate that it is a multifactorial, autoimmune condition involving T-cell mediated demyelination of the optic nerve. In common with other such diseases (e.g., MS, psoriasis, inflammatory bowel disease, rheumatoid arthritis), it has proven difficult to distinguish causative responses from bystander effects. Epidemiologic studies have implicated environmental factors as a contributing factor, including infectious agents such as certain viruses (e.g., HCMV, EBV, HHV-6, HHV-7, JCV, HTLV-1, SFV, TMEV) (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>). However, this concept remains controversial (<xref ref-type="bibr" rid="B6">6</xref>&#x2013;<xref ref-type="bibr" rid="B8">8</xref>) and, if an infectious agent is involved, it alone may not be sufficient to initiate the observed pathology. Optic neuritis is of particular interest due to its association with multiple sclerosis (MS). The visual pathway is one of the early and most commonly affected sites in MS patients in which optic nerves are demyelinated causing blurred or &#x201c;washed-out vision&#x201d; (<xref ref-type="bibr" rid="B9">9</xref>&#x2013;<xref ref-type="bibr" rid="B13">13</xref>). In about 50-70% of patients with monosymptomatic optic neuritis, clinically silent MS-like lesions are found on brain MRI (<xref ref-type="bibr" rid="B2">2</xref>), and an optic neuritis episode is a strong predictor for development of MS (<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B15">15</xref>). More recent prospective studies have demonstrated that, with extended follow-up, at least half of the patients with monosymptomatic optic neuritis will be diagnosed with MS (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B16">16</xref>&#x2013;<xref ref-type="bibr" rid="B18">18</xref>). This close relationship between optic neuritis and MS has made the optic nerve an MS-relevant issue, and the autoimmune responses in optic neuritis may reflect early events that occur in human MS.</p>
<p>To provide a framework for analysis of potential multifactorial interactions, we developed a mouse model of optic neuritis that combines overexpression of interleukin-2 (IL-2) in the context of HSV-1 infection using the recombinant HSV-IL-2 virus (<xref ref-type="bibr" rid="B19">19</xref>). Neither ocular HSV-1 infection alone nor overexpression of IL-2 alone induces optic nerve or CNS pathology. However, ocular infection with this recombinant HSV-1 that constitutively overexpresses cytokines demonstrated that HSV-IL-2 (but not HSV-IL-4, HSV-IFN-&#x3b3;, HSV-IL-12p35 or HSV-IL-12p40) elicited optic neuropathy as determined by changes in visual-evoked cortical potentials (VECPs) and typical pathologic changes in the optic nerve and CNS (<xref ref-type="bibr" rid="B20">20</xref>&#x2013;<xref ref-type="bibr" rid="B23">23</xref>). In our previous studies, knockout, depletion, and adoptive transfer approaches indicated that both CD4<sup>+</sup> and CD8<sup>+</sup> T cells contribute to the HSV-IL-2-induced optic nerve and CNS pathology (<xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B24">24</xref>). Characterization of HSV-IL-2-infected cells revealed the dysregulation of cytokines and the inhibition of T<sub>H</sub>1 differentiation which had the potential to lead to production of pathogenic T cells (<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B25">25</xref>). It is well established that both IL-17 producing CD4<sup>+</sup> (<xref ref-type="bibr" rid="B26">26</xref>) and CD8<sup>+</sup> T cells (<xref ref-type="bibr" rid="B27">27</xref>) play important roles in autoimmunity. T<sub>H</sub>17 cells have been implicated in auto-aggressive CNS pathology, and studies suggest that these cells orchestrate inflammation in diseases including psoriasis, inflammatory bowel disease, and rheumatoid arthritis (RA). T<sub>H</sub>17 cells trigger nerve damage in experimental autoimmune encephalomyelitis (EAE), and brain lesions of multiple sclerosis (MS) patients exhibit high levels of IL-17. IL-2 has been shown to promote T<sub>H</sub>17 development <italic>in vivo</italic> (<xref ref-type="bibr" rid="B28">28</xref>). In addition to T cells (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B27">27</xref>), innate lymphoid cells (ILCs), CD4<sup>&#x2212;</sup>CD8<sup>&#x2212;</sup> T cells, &#x3b3;&#x3b4;T cells, invariant natural killer (iNK) T cells, NK cells, neutrophils, mast cells and B cells have been shown to secrete IL-17 (<xref ref-type="bibr" rid="B29">29</xref>&#x2013;<xref ref-type="bibr" rid="B34">34</xref>).</p>
<p>In this study we investigated the contribution of IL-17A and three of its receptors to the development of CNS demyelination within an HSV-IL-2 model of ocular neuritis. Our data suggests that: <bold>(1)</bold> IL-17A is involved in HSV-IL-2-induced CNS demyelination; <bold>(2)</bold> production of IL-17A by both T cells and non-T cells is contributing to CNS pathology; <bold>(3)</bold> absence of either the IL-17RA, IL-17RC, IL-17RARC, or IL-17RD receptor does not block CNS demyelination in HSV-IL-2 infected mice; <bold>(4)</bold> IL-6, IL-10, or TGF&#x3b2; do not contribute to CNS demyelination in HSV-IL-2 infected mice; and <bold>(5)</bold> down regulation of genes associated with neuron projection, extension, and guidance may have contributed to demyelination, while regulation of genes associated with the pathway for ensheathment of neurons may contributed to remyelination. Collectively, these data suggest that elevation of IL-2 levels in the context of viral infection drives an auto-aggressive IL-17A response that causes optic neuritis and CNS pathology. Both T cells and non-T cells contribute to the production of IL-17A, which then affects T-cell lineage commitment and shifts the overall response to that of an auto-aggressive T<sub>H</sub>17 response.</p>
</sec>
<sec id="s2" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="s2_1">
<title>Ethics statement</title>
<p>All animal procedures were performed in strict accordance with the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research and the NIH <italic>Guide for the Care and Use of Laboratory Animals</italic> (ISBN 0-309-05377-3). The animal research protocols were approved by the Institutional Animal Care and Use Committee of Cedars-Sinai Medical Center (Protocols # 6134 and 9833).</p>
</sec>
<sec id="s2_2">
<title>Cells and virus</title>
<p>RS (rabbit skin) cells were generated in our laboratory, prepared, grown in MEM media plus 5% FBS and used as we described previously (<xref ref-type="bibr" rid="B35">35</xref>, <xref ref-type="bibr" rid="B36">36</xref>). Triple plaque-purified HSV-IL-2 and McKrae (parental virus for HSV-IL-2) were grown in RS cell monolayers as described previously (<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B37">37</xref>).</p>
</sec>
<sec id="s2_3">
<title>Mice</title>
<p>Inbred female C57BL/6J, Rag1<sup>-/-</sup>, Rag2<sup>-/-</sup>, IL-6<sup>-/-</sup> and IL-10<sup>-/-</sup> mice were obtained from the Jackson Laboratory (Bar Harbor, ME). IL-17A<sup>-/-</sup>, CD11cdnTGF-RII, and CD4dnTGF-RII mice were described previously (<xref ref-type="bibr" rid="B38">38</xref>&#x2013;<xref ref-type="bibr" rid="B40">40</xref>). IL-17RC<sup>-/-</sup> mice were developed by Genentech and were obtained from the Mutant Mouse Regional Resource Center (University of California, Davis). IL-17RA<sup>-/-</sup> and IL-17RA<sup>-/-</sup>RC<sup>-/-</sup> were developed in our Lab and described previously (<xref ref-type="bibr" rid="B41">41</xref>). IL-17RD<sup>-/-</sup> mice were obtained from the Mutant Mouse Regional Resource Center (University of California, Davis). All mice used in this study have a B6 background and were bred in-house. Only female (6 to 8-wk-old) mice were used in the study as male mice are more resistance to HSV-IL-2-induced CNS demyelination than female mice (<xref ref-type="bibr" rid="B21">21</xref>). This is comparable to observations made in other models for MS.</p>
</sec>
<sec id="s2_4">
<title>Ocular infection</title>
<p>IL-17A<sup>-/-</sup>, IL1-7RA<sup>-/-</sup>, IL-17RC<sup>-/-</sup>, IL-17RA<sup>-/-</sup>RC<sup>-/-</sup>, IL-17RD<sup>-/-</sup>, Rag1<sup>-/-</sup>, Rag2<sup>-/-</sup>, IL-6<sup>-/-</sup>, IL-10<sup>-/-</sup>, CD11cdnTGF-RII, CD4dnTGF-RII and WT control mice were infected ocularly with 2 X 10<sup>5</sup> PFU of HSV-IL-2 or WT HSV-1 strain McKrae as a control in 2&#x3bc;l of tissue culture media as an eye drop without corneal scarification as we have described previously (<xref ref-type="bibr" rid="B42">42</xref>).</p>
</sec>
<sec id="s2_5">
<title>Preparation of brain, spinal cord, and optic nerves for histological analyses</title>
<p>In our previous studies we looked at CNS demyelination in brain, spinal cord and optic nerves of HSV-IL-2 infected mice on days 5, 7, 14, 18, and 75 post infection (PI) and detected demyelination as early as day 14 PI. Thus, in this study brain, spinal cord, and optic nerves of infected mice were removed at necropsy on day 14 PI. Isolated tissues were snap frozen in an isopentane-liquid nitrogen bath and stored at &#x2013;80<bold>
<sup>&#xb0;</sup>
</bold>C. Transverse sections 8-10 &#x3bc;m thick of the entire brain, spinal cord, or optic nerve were cut, air-dried overnight, and fixed in acetone for 3&#xa0;min at 25<bold>
<sup>&#xb0;</sup>
</bold>C (<xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B43">43</xref>). Consecutive sections were used for the pathological analyses.</p>
</sec>
<sec id="s2_6">
<title>Analysis of demyelination using Luxol Fast Blue staining</title>
<p>The presence or absence of demyelination in infected mice was evaluated using LFB staining of formalin-fixed sections of optic nerve as we described previously (<xref ref-type="bibr" rid="B20">20</xref>). Every fifth section of brain, spinal cord and optic nerve was stained for LFB. The number of plaques, size of plaques, and shape of plaques on multiple fields were evaluated by investigators who were blinded to the treatment groups using serial sections of CNS tissues. The amount of myelin loss in the stained sections of brain, spinal cord and optic nerve was measured using the NIH Image J software analysis system. The areas of demyelination (clear-white) to normal tissue (blue) were quantified using 150 random sections from the brain and spinal cord, or 30 sections from the optic nerve of each animal. Demyelination in each section was confirmed by monitoring adjacent sections. The percentage of myelin loss was calculated by dividing the lesion size into the total area for each section.</p>
</sec>
<sec id="s2_7">
<title>Adoptive transfer of T cells</title>
<p>Total T cells from WT C57BL/6 or IL-17A<sup>-/-</sup> donor mice were isolated using magnetic beads as described by the manufacturer (Miltenyi Biotec, Auburn, CA). Each recipient Rag1<sup>-/-</sup>, Rag2<sup>-/-</sup> or IL-17A<sup>-/-</sup> mouse was intraperitoneally injected once with T cells equivalent to one donor mouse in 300 &#x3bc;l of MEM. The recipient mice were infected ocularly with HSV-IL-2 or control virus 2 weeks after the transfer of the cells.</p>
</sec>
<sec id="s2_8">
<title>Library preparation and sequencing</title>
<p>Brain and spinal cord from HSV-IL-2 infected IL-17A<sup>-/-</sup> and IL-17A<sup>-/-</sup> mice that received WT T cells were isolated on day 14 post ocular infection. Total RNA from brain and spinal cord of infected mice were isolated using a SMART-Seq V4 Ultra Low RNA Input Kit for Sequencing (Takara Bio USA, Inc., Mountain View, CA). Isolated RNA was used to generate double-stranded cDNA by reverse transcription for library preparation using the Nextera XT Library Preparation kit (Illumina, San Diego, CA). cDNA was quantitated using Qubit (Thermo Fisher Scientific). cDNA normalized to 80 pg/&#xb5;l was fragmented and sequencing primers were added simultaneously. A limiting-cycle PCR added Index 1 (i7) adapters, Index 2 (i5) adapters, and sequences required for cluster formation on the sequencing flow cell. Indexed libraries were pooled, washed, and the pooled library size was verified using a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA) and quantified using Qubit. Libraries were sequenced using a NextSeq 500 (Illumina) with a 1x75 bp read length and coverage of over 25M reads/sample.</p>
</sec>
<sec id="s2_9">
<title>Data analysis</title>
<p>Raw sequencing data was demultiplexed and converted to fastq format by using bcl2fastq v2.20 (Illumina, San Diego, California) and reads were aligned to the transcriptome using STAR (version 2.6.1) (<xref ref-type="bibr" rid="B44">44</xref>) and RSEM (version 1.2.28) (<xref ref-type="bibr" rid="B45">45</xref>) with default parameters, using a custom mouse GRCm38 transcriptome reference downloaded from <uri xlink:href="http://www.gencodegenes.org">http://www.gencodegenes.org</uri>, containing all protein coding based on mouse GENCODE version 24 annotation and HSV-1 gene (MN136524). Expression counts for each gene in all samples were normalized by a modified trimmed mean of the M-values normalization method. Each gene was fitted into a negative binomial generalized linear model, and the Wald test was applied to assess the differential expressions between two sample groups by DESeq2 (version 1.26.0) (<xref ref-type="bibr" rid="B46">46</xref>). Benjamini and Hochberg procedure was applied to adjust for multiple hypothesis testing, and differential expression gene (DEG) candidates were selected with a false discovery rate less than 0.1 or 0.05. DEG candidates were used for GO/KEGG enrichment analysis performed with ClusterProfileR (<xref ref-type="bibr" rid="B47">47</xref>).</p>
</sec>
<sec id="s2_10">
<title>Statistical analyses</title>
<p>Student&#x2019;s t test and ANOVA were performed using the computer program Prism (GraphPad, San Diego, CA). Results were considered statistically significant when the &#x201c;P&#x201d; value was &lt;0.05.</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<title>Results</title>
<sec id="s3_1">
<title>Absence of demyelination in the CNS of IL-17A<sup>-/-</sup> mice infected with HSV-IL-2</title>
<p>Previously we have shown that different strains of mice, independent of their MHC background, are susceptible to HSV-IL-2-induced CNS demyelination, but not to WT virus or recombinant HSV-1 expressing murine IL-4, IL-12p35, IL-12p40 or IFN-&#x3b3; (<xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B43">43</xref>). T<sub>H</sub>17 cell involvement has also been described in many autoimmune diseases (<xref ref-type="bibr" rid="B48">48</xref>&#x2013;<xref ref-type="bibr" rid="B56">56</xref>). Thus, to determine what role T<sub>H</sub>17 plays in our model of CNS demyelination, five 6-8 week old female IL-17A<sup>-/-</sup> mice of a C57BL/6 background were infected with 2 x 10<sup>5</sup> PFU/eye of HSV-IL-2 or WT McKrae control virus. Age matched female C57BL/6 mice were used as an experimental control. On day 14 post-infection (PI), optic nerve, brain and spinal cord samples were dissected. Samples were sectioned, fixed and stained with Luxol fast blue (LFB) as we described previously (<xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B43">43</xref>). Representative photomicrographs of optic nerve, brain, and spinal cord sections are shown in <xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>. No demyelination was observed in optic nerves (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1A</bold>
</xref>), brain (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1B</bold>
</xref>) or spinal cord (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1C</bold>
</xref>) of IL-17A<sup>-/-</sup> mice infected with HSV-IL-2 virus. As expected, demyelination was observed in the optic nerves (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1D</bold>
</xref>), brain (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1E</bold>
</xref>) or spinal cord (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1F</bold>
</xref>) of WT mice infected with HSV-IL-2 virus. No such lesions or other signs of demyelination were observed at this time point in optic nerves (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1G</bold>
</xref>), brain (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1H</bold>
</xref>) or spinal cord (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1I</bold>
</xref>) of the WT mice infected with HSV-1 strain McKrae. These results suggest that the absence of IL-17A blocks HSV-IL-2-induced CNS demyelination in infected mice and confirms the requirement for the overexpression of IL-2 for CNS demyelination within the model.</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Role of IL-17A in HSV-IL-2 induced CNS demyelination. Five female IL-17A<sup>-/-</sup> <bold>(A&#x2013;C)</bold> and WT C57BL/6 mice were infected ocularly with 2 X10<sup>5</sup> pfu/eye of HSV-IL-2 or WT virus as described in Materials and Methods. On day 14 PI, optic <bold>(A, D, G)</bold> nerves, brain <bold>(B, E, H)</bold>, and spinal cord <bold>(C, F, I)</bold> were collected, fixed, sectioned, and stained with LFB. Representative photomicrographs are shown. Arrows indicate areas of demyelination. x10 objective lens was used (100x mag.).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-14-1102486-g001.tif"/>
</fig>
</sec>
<sec id="s3_2">
<title>Role of IL-17A expressing T cells and non-T cells during CNS demyelination</title>
<p>Both CD4<sup>+</sup> and CD8<sup>+</sup> T cells produce IL-17A and play important roles in autoimmunity (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B27">27</xref>). Previously we have shown that both CD4<sup>+</sup> and CD8<sup>+</sup> T cells are involved in CNS demyelination (<xref ref-type="bibr" rid="B24">24</xref>). To test the hypothesis that IL-17A-producing T cells are contributing to CNS demyelination, T cells were isolated using magnetic beads from naive female IL-17A<sup>-/-</sup> mice or WT C57BL/6 mice. The cells were then adoptively transferred into Rag1<sup>-/-</sup> or Rag2<sup>-/-</sup> mice <italic>via</italic> intraperitoneal injection (i.p.). Rag1<sup>-/-</sup> or Rag2<sup>-/-</sup>mice are characterized by a complete block in T and B cell development. Two weeks after adoptive transfer, all the Rag1<sup>-/-</sup> and Rag2<sup>-/-</sup> recipient mice were infected ocularly with HSV-IL-2 virus as above. Fourteen days after infection (day 14 PI), the mice were sacrificed and optic nerves, brain and spinal cord were removed, sectioned, fixed and stained with LFB. Representative photomicrographs are shown in <xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2</bold>
</xref>.&#xa0;A summary of the data concerning the numbers and size of demyelination plaques within the optic nerve, brain and spinal cord sections from these mice are shown in <xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3</bold>
</xref>.</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Adoptive transfer of IL-17A<sup>-/-</sup> and WT T cells to Rag mice. Naive T cells were isolated from five IL-17A<sup>-/-</sup> and WT mice using a magnetic bead system. Isolated T cells were adoptively transferred <italic>via</italic> intraperitoneal injection (i.p.) into five Rag1<sup>-/-</sup> and Rag2<sup>-/-</sup> mice. Two weeks post-adoptive transfer, mice were infected ocularly with 2 X10<sup>5</sup> pfu/eye of HSV-IL-2 virus. On day 14 PI, optic nerves <bold>(A, D, G, J)</bold>, brain <bold>(B, E, H, K)</bold>, and spinal cord <bold>(C, F, I, L)</bold> samples were harvested, sectioned, and stained with LFB. The left panel depicts a Rag1<sup>-/-</sup> mouse transferred with IL17A<sup>-/-</sup> T cells <bold>(A, B, C)</bold> or wild type T cells <bold>(D, E, F)</bold>, respectively. The right panel depicts a Rag2<sup>-/-</sup> mouse transferred with IL17A<sup>-/-</sup>  T cells <bold>(G, H, I)</bold> or wild type T cells <bold>(J, K, L)</bold>, respectively. Representative sections are shown with arrows indicating areas of demyelination. x10 objective lens was used (100x mag.).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-14-1102486-g002.tif"/>
</fig>
<p>Rag1<sup>-/-</sup> mice that received T cells from IL-17A<sup>-/-</sup> mice showed demyelination in their optic nerve (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2A</bold>
</xref>), brain (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2B</bold>
</xref>) and spinal cord (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2C</bold>
</xref>). Similarly, Rag1<sup>-/-</sup> mice that received T cells from WT mice also showed demyelination in their optic nerve (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2D</bold>
</xref>), brain (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2E</bold>
</xref>) and spinal cord (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2F</bold>
</xref>). Similar to Rag1<sup>-/-</sup> mice, Rag2<sup>-/-</sup> mice that received T cells from IL-17A<sup>-/-</sup> mice showed demyelination in their optic nerve (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2G</bold>
</xref>), brain (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2H</bold>
</xref>) and spinal cord (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2I</bold>
</xref>). As expected, demyelination also was detected in optic nerve (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2J</bold>
</xref>), brain (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2K</bold>
</xref>) and spinal cord (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2L</bold>
</xref>) of Rag2<sup>-/-</sup> mice that received T cells from WT mice. These results suggest that the absence of IL-17A expression in T cells is not adequate to prevent CNS demyelination.</p>
<p>In addition to T cells, other cell types such as ILCs, CD4<sup>&#x2212;</sup>CD8<sup>&#x2212;</sup> T cells, &#x3b3;&#x3b4;T cells, invariant natural killer (iNK) T cells, NK cells, neutrophils, mast cells and B cells express IL-17A (<xref ref-type="bibr" rid="B29">29</xref>&#x2013;<xref ref-type="bibr" rid="B34">34</xref>). Thus, we next tested if transfer of T cells from WT mice to IL-17A<sup>-/-</sup> mice could induce CNS demyelination after HSV-IL-2 infection. T cells were isolated using magnetic beads from naive female WT C57BL/6 mice and the cells injected intraperitoneally into IL-17A<sup>-/-</sup> recipient mice. Two-weeks after adoptive transfer, all the recipient mice and control IL-17A<sup>-/-</sup> mice without T cells transfer were infected ocularly with HSV-IL-2 virus. Fourteen days post infection, the mice were sacrificed, and optic nerves, brain and spinal cord were removed, sectioned, fixed and stained with LFB. Representative photomicrographs are shown in <xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4</bold>
</xref>, and a summary of the data concerning the numbers and size of demyelination of the optic nerve, brain and spinal cord sections from mice infected with HSV-IL-2 are shown in <xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3</bold>
</xref>. IL-17A<sup>-/-</sup> mice that received T cells from WT mice demonstrated demyelination in their optic nerve (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4A</bold>
</xref>), brain (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4B</bold>
</xref>) and spinal cord (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4C</bold>
</xref>), while as expected control IL-17A<sup>-/-</sup> mice similar to <xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref> (above) showed no CNS demyelination (<xref ref-type="fig" rid="f4">
<bold>Figures&#xa0;4D&#x2013;F</bold>
</xref>). The results of adoptive transfer of WT T cells into the IL-17A<sup>-/-</sup> mouse provide further evidence that T cells expressing IL-17A contribute to CNS demyelination in the absence of IL-17A production by non-T cells.</p>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>Number and size of demyelination plaques in CNS of infected HSV-IL-2 mice. The entire brain, spinal cord, and optic nerves of each of the 5 animals described in <xref ref-type="fig" rid="f1">
<bold>Figures&#xa0;1</bold>
</xref>, <xref ref-type="fig" rid="f2">
<bold>2</bold>
</xref>, <xref ref-type="fig" rid="f4">
<bold>4</bold>
</xref>&#x2013;<xref ref-type="fig" rid="f6">
<bold>6</bold>
</xref> were sectioned and every 5th slide of each tissue was stained. The number <bold>(A, C, E)</bold> and size of <bold>(B, D, F)</bold> demyelination plaques in the entire sections of brain, spinal cord <bold>(E, F)</bold> and optic nerves <bold>(A, B)</bold> were counted and measured, respectively. Data are presented as number of plaques per total sections or size of plaques per total sections. Data are presented as mean number of demyelination plaques or mean of size of demyelination plaques using a total of 150 sections for brain and spinal cord and 30 sections for optic nerve from 5 mice per group.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-14-1102486-g003.tif"/>
</fig>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>Adoptive transfer of WT T cells to IL-17A<sup>-/-</sup> mice. Naive T cells were isolated from 5 WT mice. Magnetically isolated cells were transferred by intraperitoneal injection into 5 recipient IL-17A<sup>-/-</sup> mice. Two weeks post-adoptive transfer, recipient mice <bold>(A, B, C)</bold> and control IL-17A<sup>-/-</sup> mice without T cells transfer <bold>(D, E, F)</bold> were infected ocularly with 2 X10<sup>5</sup> pfu/eye of HSV-IL-2 virus. Representative optic nerves <bold>(A, D)</bold>, brain <bold>(B, E)</bold>, and spinal cord <bold>(C, F)</bold> on day 14 PI from infected mice are shown. Arrows indicate areas of demyelination. x10 objective lens was used (100x mag.).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-14-1102486-g004.tif"/>
</fig>
</sec>
<sec id="s3_3">
<title>Role of IL-17R in HSV-IL-2-induced demyelination</title>
<p>The IL-17 receptor (IL-17R) family has five known members (<italic>i.e.</italic>, IL-17RA, IL-17RB, IL-17RC, IL-17RD, and IL-17RE) (<xref ref-type="bibr" rid="B57">57</xref>, <xref ref-type="bibr" rid="B58">58</xref>). However, the functions of these receptors in HSV-IL-2-induced CNS demyelination are not known. IL-17A binds to IL-17RA and IL-17RC (<xref ref-type="bibr" rid="B59">59</xref>, <xref ref-type="bibr" rid="B60">60</xref>). IL-17RC is an obligate co-receptor with IL-17RA for signaling induced by IL-17A and IL-17F (<xref ref-type="bibr" rid="B61">61</xref>). We first tested if the absence of IL-17RA or IL-17RC blocks CNS demyelination following infection with the HSV-IL-2 virus. Five female IL-17RA<sup>-/-</sup> and IL-17RC<sup>-/-</sup> mice in C57BL/6 background were infected with 2 X 10<sup>5</sup> PFU/eye of HSV-IL-2 virus. On day 14 PI, optic nerves, brain, and spinal cord were isolated and stained with LFB as described in materials and methods. Representative photomicrographs of each type of section are shown in <xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5</bold>
</xref>. Upon ocular infection of IL-17RA<sup>-/-</sup> and IL-17RC<sup>-/-</sup> mice with HSV-IL-2, demyelination was detected in all samples of both IL-17RA<sup>-/-</sup> (<xref ref-type="fig" rid="f5">
<bold>Figures&#xa0;5A&#x2013;C</bold>
</xref>) and IL-17RC<sup>-/-</sup> (<xref ref-type="fig" rid="f5">
<bold>Figures&#xa0;5D&#x2013;F</bold>
</xref>) infected mice.</p>
<fig id="f5" position="float">
<label>Figure&#xa0;5</label>
<caption>
<p>Role of IL-17 receptors in HSV-IL-2 induced CNS demyelination. Five female IL-17RA<sup>-/-</sup> <bold>(A, B, C)</bold>, IL-17RC<sup>-/-</sup> <bold>(D, E, F)</bold>, IL-17RA<sup>-/-</sup>RC<sup>-/-</sup> <bold>(G, H, I)</bold> and IL-17RD<sup>-/-</sup> <bold>(J, K, L)</bold> mice were infected ocularly with 2 X10<sup>5</sup> pfu/eye of HSV-IL-2 virus. On day 14 PI, optic nerves <bold>(A, D, G, J)</bold>, brain <bold>(B, E, H, K)</bold>, and spinal cord <bold>(C, F, I, L)</bold> were collected, fixed, sectioned, and stained with LFB. Representative photomicrographs are shown. Arrows indicate areas of demyelination. x10 objective lens was used (100x mag.).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-14-1102486-g005.tif"/>
</fig>
<p>Since IL-17A binds to both IL-17RA and IL-17RC, detection of demyelination in IL-17RA<sup>-/-</sup> and IL-17RC<sup>-/-</sup> mice may suggest that the other receptor compensates for the missing receptor for binding to IL-17A. Thus, to determine if the absence of both RA and RC molecules is required to block CNS demyelination in infected mice, we generated mice lacking a combination of both IL-17RA and IL-17RC as we described previously (<xref ref-type="bibr" rid="B41">41</xref>). We infected IL-17RA<sup>-/-</sup>RC<sup>-/-</sup> mice with HSV-IL-2 and looked for demyelination in optic nerve, brain, and spinal cord sections of infected mice as above. Similar to only IL-17RA<sup>-/-</sup> or IL-17RC<sup>-/-</sup> infected mice, the absence of both RA and RC in IL-17RA<sup>-/-</sup>RC<sup>-/-</sup> mice did not block demyelination in optic nerves (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5G</bold>
</xref>), brain (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5H</bold>
</xref>) or spinal cord (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5I</bold>
</xref>) of infected mice. Thus, these results suggest that presence of IL-17RA and IL-17RC are not required for induction of CNS demyelination by IL-17A. Finally, we looked at the possible involvement of IL-17RD in CNS demyelination. IL-17RD<sup>-/-</sup> mice were infected ocularly as described above with HSV-IL-2 virus and optic nerve, brain, and spinal cord of infected mice were isolated on day 14 PI. Isolated tissues were dissected, post-fixed and stained with LFB as above and representative photomicrographs of optic nerve, brain and spinal cord sections from mice infected with HSV-IL-2 virus are shown in <xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5 J&#x2013;L</bold>
</xref>. Similar to the results stated above we detected demyelination in the optic nerves (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5J</bold>
</xref>), brain (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5K</bold>
</xref>) and spinal cord (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5L</bold>
</xref>) of IL-17RD<sup>-/-</sup> mice. Collectively, this data suggests that IL-17A plays a critical role in the HSV-IL-2-induced demyelination and that the absence of all the five IL-17 receptors may be necessary to achieve similar blocking of demyelination as with IL-17A<sup>-/-</sup> infected mice. However, we cannot rule out the possibility that IL-17RB or IL-17RE alone contributes to CNS demyelination or unknown IL-17A receptor contributing to demyelination.</p>
</sec>
<sec id="s3_4">
<title>Role of IL-6, IL-10, and TGF&#x3b2; in HSV-IL-2 induced demyelination in infected mice</title>
<p>T<sub>H</sub>17 cell development is driven by numerous cytokines including TGF-&#x3b2;, IL-6, and IL-10 (<xref ref-type="bibr" rid="B60">60</xref>, <xref ref-type="bibr" rid="B62">62</xref>), and the generation of pathogenic T<sub>H</sub>17 is dependent on the absence of TGF&#x3b2;, IL-6 and IL-10 (<xref ref-type="bibr" rid="B63">63</xref>, <xref ref-type="bibr" rid="B64">64</xref>). Previously, it was shown that levels of TGF-&#x3b2; or IL-6 control the balance between T<sub>H</sub>17 and Treg cells, and their imbalance in favor of the former will break the immune homeostasis in the host and result in the development of autoimmune diseases (<xref ref-type="bibr" rid="B65">65</xref>). It was shown that TGF-&#x3b2; secreted by Treg cells was not required for T<sub>H</sub>17 cell development; rather the regulation of IL-2 by Treg cells was found to play an important role in the generation of T<sub>H</sub>17 cells (<xref ref-type="bibr" rid="B28">28</xref>). Thus, to test the roles of IL-6, IL-10 and TGF-&#x3b2; in demyelination, IL-6<sup>-/-</sup>, IL-10<sup>-/-</sup>, CD11cdnTGF-RII, and CD4dnTGF-RII female transgenic mice were ocularly infected with HSV-IL-2 as above. The latter two mice express a dominant-negative form of TGF-&#x3b2; RII under the control of either the CD11c (<xref ref-type="bibr" rid="B38">38</xref>) or CD4 promoter (<xref ref-type="bibr" rid="B39">39</xref>).</p>
<p>Optic nerve, brain, and spinal cord of infected mice that were either IL-6<sup>-/-</sup> or IL-10<sup>-/-</sup> were isolated on day 14 PI, sectioned, fixed and stained with LFB as above, and representative photomicrographs of optic nerve, brain and spinal cord sections from infected mice are shown in <xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6</bold>
</xref>. IL-6<sup>-/-</sup> infected mice showed demyelination in their optic nerves (<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6A</bold>
</xref>), brain (<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6B</bold>
</xref>) and spinal cord (<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6C</bold>
</xref>). Similarly, demyelination was detected in optic nerves (<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6D</bold>
</xref>), brain (<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6E</bold>
</xref>) and spinal cord (<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6F</bold>
</xref>) of IL-10<sup>-/-</sup> infected mice.</p>
<p>Transforming growth factor-beta (TGF-&#x3b2;) is a pleiotropic cytokine that is present on most cell types and acts as a switch to regulate processes such as immune function, cell proliferation and differentiation (<xref ref-type="bibr" rid="B66">66</xref>&#x2013;<xref ref-type="bibr" rid="B68">68</xref>). To overcome the developmental problems associated with the generation of TGF-&#x3b2; knockout mice (<xref ref-type="bibr" rid="B69">69</xref>&#x2013;<xref ref-type="bibr" rid="B72">72</xref>), we used dominant-negative transgenic mice in which TGF-&#x3b2; signaling by immune cells was blocked (<xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B39">39</xref>). In CD11cdnTGF-RII mice, the innate immune cells do not respond to TGF-&#x3b2; ligands, while in CD4dnTGF-RII mice, T-cells do not respond to TGF-&#x3b2;. CD11cdnTGF-RII and CD4dnTGF-RII mice were ocularly infected with HSV-IL-2 virus as above. Optic nerve, brain, and spinal cord of infected CD11cdnTGF-RII and CD4dnTGF-RII mice were isolated on day 14 PI. Isolated tissues were sectioned, fixed, and stained with LFB as above, and representative photomicrographs of optic nerve, brain and spinal cord sections from mice infected with HSV-IL-2 virus are shown in <xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7</bold>
</xref>. CD11cdnTGF-RII infected mice showed demyelination in their optic nerves (<xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7A</bold>
</xref>), brain (<xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7B</bold>
</xref>) and spinal cord (<xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7C</bold>
</xref>). Similarly, demyelination was detected in optic nerves (<xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7D</bold>
</xref>), brain (<xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7E</bold>
</xref>) and spinal cord (<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6F</bold>
</xref>) of CD4dnTGF-RII infected mice.</p>
<fig id="f6" position="float">
<label>Figure&#xa0;6</label>
<caption>
<p>Role of IL-6 and IL-10 in HSV-IL-2 induced CNS demyelination. Five female IL-6<sup>-/-</sup> <bold>(A, B, C)</bold> and IL-10<sup>-/-</sup> <bold>(D, E, F)</bold> mice were infected ocularly with 2 X10<sup>5</sup> pfu/eye of HSV-IL-2 virus. On day 14 PI, optic nerves <bold>(A, D)</bold>, brain <bold>(B, E)</bold>, and spinal cord <bold>(C, F)</bold> were collected, fixed, sectioned, and stained with LFB. Representative photomicrographs are shown. Arrows indicate areas of demyelination. x10 objective lens was used (100x mag.).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-14-1102486-g006.tif"/>
</fig>
<fig id="f7" position="float">
<label>Figure&#xa0;7</label>
<caption>
<p>Role of TGF&#x3b2; in HSV-IL-2 induced CNS demyelination. Five female CD11cdnTGF-RII <bold>(A, B, C)</bold> and CD4dnTGF-RII <bold>(D, E, F)</bold> mice were infected ocularly with 2 X10<sup>5</sup> pfu/eye of HSV-IL-2 virus. On day 14 PI, optic nerves <bold>(A, D)</bold>, brain <bold>(B, E)</bold>, and spinal cord <bold>(C, F)</bold> were collected, fixed, sectioned, and stained with LFB. Representative photomicrographs are shown. Arrows indicate areas of demyelination. x10 objective lens was used (100x mag.).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-14-1102486-g007.tif"/>
</fig>
<p>These results suggest that the absence of IL-6, IL-10 or TGF-&#x3b2; signaling in the T cells or innate immune cells had no effect in blocking CNS demyelination in HSV-IL-2 infected mice.</p>
</sec>
<sec id="s3_5">
<title>Size and number of plaques in CNS of infected mice</title>
<p>To quantify the extent of the demyelination, we counted the number and measured the size of the observed demyelination plaques in the brains, spinal cords and optic nerves of five females each of WT, IL-17A<sup>-/-</sup>, Rag1<sup>-/-</sup> + WT T cell, Rag1<sup>-/-</sup> + IL-17A<sup>-/-</sup> T cell, IL-17A<sup>-/-</sup> + WT T cell, IL-17RA<sup>-/-</sup>, CD11cdnTGF-RII, CD4dnTGF-RII, IL-6<sup>-/-</sup>, and IL-10<sup>-/-</sup> mice described above, and we counted the number and the size of observed plaques in the optic nerve, brain and spinal cord of infected mice as we described previously (<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B73">73</xref>). The data are shown as the number of sections showing demyelination plaques per total stained sections as well as area of demyelination per section (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3</bold>
</xref>). As expected, no plaques were detected in optic nerves, brain, and spinal cord of IL-17A<sup>-/-</sup> infected mice (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3</bold>
</xref>).</p>
<p>In contrast to IL-17A<sup>-/-</sup> mice, Rag1<sup>-/-</sup> + WT T cell, Rag1<sup>-/-</sup> + IL-17A<sup>-/-</sup> T cell, IL-17RA<sup>-/-</sup>, IL-6<sup>-/-</sup>, IL-10<sup>-/-</sup>, CD11cdnTGF-RII, and CD4dnTGF-RII infected mice had similar number of plaques per optic nerve section as WT mice (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3A</bold>
</xref>). However, IL-17A<sup>-/-</sup> mice that received T cell from WT mice had lower number of plaques per section of optic nerve (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3A</bold>
</xref>). Similar to lower number of plaques in IL-17A<sup>-/-</sup> + WT T cell mice, these mice also had lower plaque size than other infected mice (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3B</bold>
</xref>, IL-17A<sup>-/-</sup> + WT T cell group). Plaque size in Rag1<sup>-/-</sup> + WT T cell, Rag1<sup>-/-</sup> + IL-17A<sup>-/-</sup> T cell, IL-17A<sup>-/-</sup> + WT T cell, IL-17RA<sup>-/-</sup>, IL-6<sup>-/-</sup>, IL-10<sup>-/-</sup>, CD11cdnTGF-RII, and CD4dnTGF-RII mice was similar to that of WT mice (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3B</bold>
</xref>, P&gt;0.05). The number of plaques (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3C</bold>
</xref>) and size of plaques (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3D</bold>
</xref>) in the brain of infected mice were also determined as above. The number of plaques in the brain of all groups of infected mice, including IL-17A<sup>-/-</sup> mice that received T cells from WT mice, were similar to that of WT mice (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3C</bold>
</xref>, P&gt;0.05). Similar to the number of plaques, the severity of plaque size in the brain section of the above infected mice were similar to each other in comparison to WT mice (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3D</bold>
</xref>, P&gt;0.05). The number of HSV-IL-2-induced plaques detected in the spinal cord was similar between WT mice and Rag1<sup>-/-</sup> + WT T cell, Rag1<sup>-/-</sup> + IL-17A<sup>-/-</sup> T cell, IL-17RA<sup>-/-</sup>, IL-6<sup>-/-</sup>, IL-10<sup>-/-</sup>, CD11cdnTGF-RII, and CD4dnTGF-RII mice (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3E</bold>
</xref>
<bold>, P&gt;0.05)</bold>. In contrast, less plaques were detected in the spinal cord of IL-17A<sup>-/-</sup> mice that received T cells from WT mice than other group of infected mice (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3E</bold>
</xref> P&lt;0.05). Finally, no significant differences were observed in the size of plaques detected in the spinal cord of all groups of mice compared with WT control mice except IL-17A<sup>-/-</sup> mice that received T cells from WT mice (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3F</bold>
</xref>, P&gt;0.05).</p>
<p>Overall, except for the lower number of plaques and size of plaques in the optic nerve and spinal cord, but not brain, of IL-17A<sup>-/-</sup> mice that received T cells from WT mice, the absence of IL-17RA, IL-6, IL-10, and TGF&#x3b2; did not affect the number or size of plaques in the optic nerve, brain or spinal cord of infected mice compared with WT mice. Thus, this study suggests that both IL-17A-expressing T cells and non-T cells contribute to CNS demyelination.</p>
</sec>
<sec id="s3_6">
<title>Gene expression profiles in brain and spinal cord of HSV-IL-2 infected IL-17A<sup>-/-</sup> mice after T cell transfer</title>
<p>The above results suggest that IL-17A<sup>-/-</sup> mice have no demyelination in their CNS, while transfer of isolated T cells from WT mice to recipient IL-17A<sup>-/-</sup> mice caused CNS demyelination (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4</bold>
</xref>). To further characterize changes induced in the IL-17A<sup>-/-</sup> mice by T cell transfer that leads to CNS demyelination, we used an RNA-seq-based transcriptome analysis approach. T cells from spleens of naive female WT C57BL/6 mice were isolated using magnetic beads and the cells injected intraperitoneally into IL-17A<sup>-/-</sup> recipient mice. Two weeks after the adoptive transfer, the recipient IL-17A<sup>-/-</sup> mice as well as control IL-17A<sup>-/-</sup> mice were infected ocularly with HSV-IL-2 virus. Fourteen days after infection, the mice were sacrificed and total cells from brains and spinal cords of infected mice were isolated. Total RNA from isolated cells from brain and spinal cord of infected mice was extracted and libraries were prepared and sequenced as we described in Materials and Methods. As shown in <xref ref-type="fig" rid="f8">
<bold>Figure&#xa0;8</bold>
</xref> (brain), the transcriptome analysis of the brain of infected IL-17A<sup>-/-</sup> mice showed an upregulation of expression levels of 29 genes, (greater than 2-fold increase; in red), while the brain of T cell recipient infected IL-17A<sup>-/-</sup> mice, 149 genes were upregulated. Downregulation of 109 genes was found in IL-17A<sup>-/-</sup> brain (greater than 2-fold decrease, p&lt;0.05; in blue) and 271 genes in brain of recipient IL-17A<sup>-/-</sup> mice. There were 20 and 50 common genes between the two groups that were upregulated (in red) and downregulated (in blue), respectively. For the spinal cord (<xref ref-type="fig" rid="f8">
<bold>Figure&#xa0;8</bold>
</xref>) of infected IL-17A<sup>-/-</sup> mice, 30 genes were upregulated (in red), and 49 genes were downregulated (in blue), while in the T cell transfer group, 602 genes were upregulated (in red) and 616 downregulated (in blue). There were 10 and 11 common genes between the two groups that were upregulated and downregulated, respectively.</p>
<fig id="f8" position="float">
<label>Figure&#xa0;8</label>
<caption>
<p>Venn diagram of upregulated, downregulated, and common genes in brain and spinal cord of infected mice. Five IL-17A<sup>-/-</sup> mice with and without T cell transfer from 5 WT mice were infected with 2 X10<sup>5</sup> pfu/eye of HSV-IL-2 virus and T cells from the brain and spinal cord of infected mice on 14 days PI were isolated. Brains and spinal cords from 5 naive mice of the same age were also isolated and used to normalize gene expression in infected mice. The transcriptomes of brain and spinal cord of IL-17A<sup>-/-</sup> infected mice were compared with the corresponding tissue in mice that received T cells from WT mice. Venn diagram shows the numbers of genes uniquely or commonly detected in brain and spinal cord of infected IL-17A<sup>-/-</sup> mice with and without T cells transfer. Red dots show upregulated genes, while blue dots show downregulated genes. Data are based on three independent replicates.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-14-1102486-g008.tif"/>
</fig>
<p>We next compared the gene expression patterns between brains and spinal cords of the two groups of infected mice with and without T cell transfer, and a Venn diagram of significantly different genes shared by the four groups and analyzed by Bioinformatics &amp; Evolutionary Genomics is shown in <xref ref-type="fig" rid="f9">
<bold>Figure&#xa0;9</bold>
</xref>. There was a total of 103 genes in common between brain and spinal cord of T cells recipient mice (<xref ref-type="fig" rid="f9">
<bold>Figure&#xa0;9</bold>
</xref>). From the 103 common genes, 60 genes were upregulated between the two groups, while 43 genes were downregulated. Examination of the gene ontology (GO) terms enriched among the upregulated and downregulated 103 genes in brain and spinal cord of mice that received T cells and had demyelination was carried out using GO profiler (<xref ref-type="fig" rid="f10">
<bold>Figure&#xa0;10</bold>
</xref>). In demyelinated brain and spinal cord of infected mice, the GO terms enriched amongst the 60 upregulated genes included (<xref ref-type="fig" rid="f10">
<bold>Figure&#xa0;10</bold>
</xref>): &#x201c;oxidative phosphorylation&#x201d;; &#x201c;Oligodendrocyte differentiation&#x201d;; &#x201c;glial cell development&#x201d;; &#x201c;axon ensheathment in central nervous system&#x201d;; &#x201c;central nervous system myelination&#x201d;; &#x201c;axon ensheathment&#x201d;; &#x201c;ensheathment of neurons&#x201d;; &#x201c;myelination&#x201d;; &#x201c;myelin sheath&#x201d;; and &#x201c;structural constituent of myelin sheath&#x201d;. The following genes were associated with these pathways: <italic>MOBP, MBP, PLP1, RPS5, MAL, NDUFA7, ARPC1B, GJC3,TSPAN2</italic>, and <italic>ATP5H. PLP1, MBP, MOBP, MAL, GJC3, TSPAN2</italic> are known to be expressed in myelin, and some of gene products are abundant enough to be detected in a proteomic analysis of the mouse myelin (<xref ref-type="bibr" rid="B74">74</xref>), which agrees with GO terms related to myelin and myelinating process. Function of the above upregulated genes in brains and spinal cords of demyelinated mice are presented in <xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>. Also, proteins encoded by human orthologs of <italic>PLP1, MBP</italic>, and <italic>MOBP</italic> are known to be antigens recognized by CD4<sup>+</sup> T cells in multiple sclerosis patients (<xref ref-type="bibr" rid="B75">75</xref>). Upregulation of <italic>PLP1, MBP, MOBP, MAL, GJC3, TSPAN2</italic> may suggest that some remyelination is occurring in infected mice. This is in line with our previous study that we have shown by electron microscopy (EM) that some remyelination was occurring in brains and spinal cords of HSV-IL-2 infected mice (<xref ref-type="bibr" rid="B20">20</xref>). However, no correlation was found with regards to upregulation of <italic>RPS5</italic>, <italic>NDUFA7, ARPC1B</italic>, and <italic>ATP5H</italic> with EAE, MS or other models of CNS demyelination-remyelination.</p>
<fig id="f9" position="float">
<label>Figure&#xa0;9</label>
<caption>
<p>Comparison of transcriptome analysis of upregulated and downregulated common genes in cells isolated from brain and spinal cord of infected mice with demyelination. The transcriptomes of cells isolated from brains and spinal cords of HSV-IL-2-infected IL-17A<sup>-/-</sup> mice with and without T cells transfer and described above in <xref ref-type="fig" rid="f8">
<bold>Figure&#xa0;8</bold>
</xref> were compared after normalization with that of their uninfected counterparts. In mice that received T cells and showed demyelination, we detected 103 genes in common between the brain and spinal cord. In mice with CNS demyelination 60 of the common genes were upregulated, while 43 genes were down regulated. Data are based on three independent replicates.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-14-1102486-g009.tif"/>
</fig>
<fig id="f10" position="float">
<label>Figure&#xa0;10</label>
<caption>
<p>GO term analysis of the pathways for the 103 common genes in brain and spinal cord of T cell recipient mice with demyelination. Bars represent log-converted p-values and minus log-converted p-values for upregulated and downregulated genes, respectively, showing statistical significance for 60 genes that were upregulated and 43 genes that were downregulated in T cell recipient mice with CNS demyelination. The GO terms were ranked according to statistical significance and the top GO terms for the 60 upregulated genes and the top GO terms for the 43 downregulated genes pathways are shown. Data are based on three independent replicates.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-14-1102486-g010.tif"/>
</fig>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Genes associated with upregulation of signaling pathways and their functions in brain and spinal cord of demyelinated mice.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="center">Gene</th>
<th valign="top" align="center">Gene Function</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">MOBP (myelin oligodendrocytes basic protein)</td>
<td valign="top" align="left">Major component of central nervous system</td>
</tr>
<tr>
<td valign="top" align="left">MBP (myelin basic protein)</td>
<td valign="top" align="left">A major constituent of the myelin sheath</td>
</tr>
<tr>
<td valign="top" align="left">PLP1 (proteolipid protein 1)</td>
<td valign="top" align="left">A structural constituent of myelin sheath</td>
</tr>
<tr>
<td valign="top" align="left">RPS5 (ribosomal protein S5)</td>
<td valign="top" align="left">A structural constituent of ribosome</td>
</tr>
<tr>
<td valign="top" align="left">MAL (myelin and lymphocyte protein, T cell differentiation protein)</td>
<td valign="top" align="left">A highly hydrophobic integral membrane protein, which play a role in the formation, stabilization, and maintenance of glycosphingolipid-enriched membrane microdomains</td>
</tr>
<tr>
<td valign="top" align="left">NDUFA7 (NADH:ubiquinone oxidoreductase subunit A7)</td>
<td valign="top" align="left">a subunit of the NADH-ubiquinone oxidoreductase (complex I) enzyme, which is the first enzyme complex in the mitochondrial electron transport chain</td>
</tr>
<tr>
<td valign="top" align="left">ARPC1B (actin related protein 2/3 complex, subunit 1&#x3b2;)</td>
<td valign="top" align="left">A structural constituent of actin cytoskeleton, which mediates actin nucleation.</td>
</tr>
<tr>
<td valign="top" align="left">GJC3 (gap junction protein, &#x3b3;3)</td>
<td valign="top" align="left">Forming gap junctions to connect the cytoplasm of two contacting cells</td>
</tr>
<tr>
<td valign="top" align="left">TSPAN2 (tetraspanin 2)</td>
<td valign="top" align="left">A member of tetraspanin family of membrane protein with 4 transmembrane domains. Tetraspanins regulate the trafficking and function of other membrane proteins</td>
</tr>
<tr>
<td valign="top" align="left">ATP5H (ATP synthase, H<sup>+</sup> transporting, mitochondrial F0 complex, subunit D)</td>
<td valign="top" align="left">Involved in mitochondrial ATP synthesis coupled proton transport</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>The following pathways were associated with the downregulation of the 43 genes in demyelinated brain and spinal cord of infected mice (<xref ref-type="fig" rid="f10">
<bold>Figure&#xa0;10</bold>
</xref>): &#x201c;calcium ion binding&#x201d;; &#x201c;metal ion binding&#x201d;; &#x201c;Phagosome&#x201d;; &#x201c;cation binding&#x201d;; &#x201c;ion binding&#x201d;; &#x201c;Spinal cord injury&#x201d;; &#x201c;axon extension involved in axon guidance&#x201d;; &#x201c;neuron projection extension involved in neuron projection guidance&#x201d;; &#x201c;Calmodulin binding&#x201d;; and &#x201c;dorsal/ventral axon guidance&#x201d;. The following genes were associated with these downregulated pathways: <italic>AK5, ATP8A2, ATP2B4, C3, CPNE6, DYNC1H1, GM2004, NOS1, NRP2, H2-Q6, H2-Q7, HSPA2, HYOU1, ITGB2, LRP1, PLXNA2, RPS6KA2, SLIT1, SLIT2, TIMP2, XDH, UBR4</italic>, and 11 protocadherin genes, including <italic>PCDH1, PCDH8, PCDHGA2, PCDHGA3, PCDHGA4, PCDHGA5, PCDHGA6, PCDHGA7, PCDHGA9, PCDHGB5</italic>, and <italic>PCDHB9.</italic> Among these genes, <italic>Nrp2, Slit1, Slit2, Plxna2</italic>, and 11 protocadherin genes are involved in neural circuit formation (<xref ref-type="bibr" rid="B76">76</xref>&#x2013;<xref ref-type="bibr" rid="B78">78</xref>). Upregulation of <italic>C3, Nrp2, Lrp1</italic> was observed in demyelinating disease (<xref ref-type="bibr" rid="B79">79</xref>&#x2013;<xref ref-type="bibr" rid="B81">81</xref>). The products of <italic>C3</italic> and <italic>Lrp1</italic> were also shown to play a role in pathogenesis of multiple sclerosis or EAE (<xref ref-type="bibr" rid="B82">82</xref>, <xref ref-type="bibr" rid="B83">83</xref>) and the product of <italic>Nrp2</italic> is involved in the remyelinating process in demyelinating lesions (<xref ref-type="bibr" rid="B80">80</xref>). Additionally, <italic>Timp2</italic> and <italic>Nos1</italic> are assumed to be involved in the pathogenesis of multiple sclerosis (<xref ref-type="bibr" rid="B84">84</xref>, <xref ref-type="bibr" rid="B85">85</xref>). Function of the above downregulated genes in brains and spinal cords of demyelinated mice are presented in <xref ref-type="table" rid="T2">
<bold>Table&#xa0;2</bold>
</xref>.</p>
<table-wrap id="T2" position="float">
<label>Table&#xa0;2</label>
<caption>
<p>Genes associated with downregulation of signaling pathways and their functions in brain and spinal cord of demyelinated mice.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="center">Gene</th>
<th valign="top" align="center">Gene function</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">AK5 (adenylate kinase 5)</td>
<td valign="top" align="left">A nucleoside monophosphate kinase which catalyzes the reversible phosphorylation between nucleoside triphosphates and monophosphates</td>
</tr>
<tr>
<td valign="top" align="left">ATP8A2 (ATPase, aminophospholipid transporter-like, class I, type 8A, member 2)</td>
<td valign="top" align="left">A transmembrane protein that have aminophospholipid flippase activity driven by ATP</td>
</tr>
<tr>
<td valign="top" align="left">ATP2B4 (Ca<sup>++</sup> transporting, plasma membrane 4)</td>
<td valign="top" align="left">A plasma membrane Ca<sup>++</sup> pup driven by ATP</td>
</tr>
<tr>
<td valign="top" align="left">C3 (complement component 3)</td>
<td valign="top" align="left">A complement protein which plays a central role in the classical, alternative and lectin activation pathways of the complement system</td>
</tr>
<tr>
<td valign="top" align="left">CPNE6 (copine VI)</td>
<td valign="top" align="left">A calcium-dependent membrane-binding protein.</td>
</tr>
<tr>
<td valign="top" align="left">DYNC1H1 (dynein cytoplasmic 1 heavy chain 1)</td>
<td valign="top" align="left">A subunit of the cytoplasmic dynein complex, which mediate various types of intracellular motility</td>
</tr>
<tr>
<td valign="top" align="left">GM2004 (predicted gene 2004)</td>
<td valign="top" align="left">A zinc finger protein</td>
</tr>
<tr>
<td valign="top" align="left">NOS1 (nitric oxide synthase 1, neuronal)</td>
<td valign="top" align="left">A nitric-oxide synthase</td>
</tr>
<tr>
<td valign="top" align="left">NRP2 (neuropilin 2)</td>
<td valign="top" align="left">A receptor protein that binds to semaphorins, which plays various roles, including neural circuit formation</td>
</tr>
<tr>
<td valign="top" align="left">H2-Q6 and H2-Q7 (histocompatibility 2, Q region locuses 6&amp;7)</td>
<td valign="top" align="left">A part of MHC class I protein complex</td>
</tr>
<tr>
<td valign="top" align="left">HSPA2 (heat shock protein 2)</td>
<td valign="top" align="left">Protein folding chaperone</td>
</tr>
<tr>
<td valign="top" align="left">HYOU1 (hypoxia up-regulated 1)</td>
<td valign="top" align="left">Negative regulation of endoplasmic reticulum stress-induced neuron intrinsic apoptotic signaling pathway</td>
</tr>
<tr>
<td valign="top" align="left">ITGB2 (integrin &#x3b2;2)</td>
<td valign="top" align="left">Contributes to laminin binding activity</td>
</tr>
<tr>
<td valign="top" align="left">LRP1 (low density lipoprotein receptor-related protein 1)</td>
<td valign="top" align="left">A transmembrane glycoprotein, which interacts with broad range of secreted proteins and cell surface molecule.</td>
</tr>
<tr>
<td valign="top" align="left">PLXNA2 (plexin A2)</td>
<td valign="top" align="left">A receptor for semaphorins and involves in axonal guidance</td>
</tr>
<tr>
<td valign="top" align="left">RPS6KA2 (ribosomal protein S6 kinase, polypeptide 2)</td>
<td valign="top" align="left">A serine/threonine protein kinase, which intermediates the cellular response to several growth factors</td>
</tr>
<tr>
<td valign="top" align="left">SLIT1 and SLIT2 (Slit guidance ligands 1&amp;2)</td>
<td valign="top" align="left">A cell surface receptor for Robo family receptors, which plays roles in axon guidance</td>
</tr>
<tr>
<td valign="top" align="left">TIMP2 (tissue inhibitor of metalloproteinase 2)</td>
<td valign="top" align="left">A metalloendopeptidase inhibitor</td>
</tr>
<tr>
<td valign="top" align="left">XDH (xanthine dehydrogenase)</td>
<td valign="top" align="left">An enzyme that catalyzes xanthine dehydrogenation and oxidation</td>
</tr>
<tr>
<td valign="top" align="left">UBR4 (ubiquitin protein ligase E3 component n-recognin 4)</td>
<td valign="top" align="left">Ubiquitin protein ligase</td>
</tr>
<tr>
<td valign="top" align="left">PCDH (protocadherin) family (i.e., PCDH1, PCDH8, PCDH&#x3b3;A2, PCDH&#x3b3;A3, PCDH&#x3b3;A4, PCDH&#x3b3;A5, PCDH&#x3b3;A6, PCDH&#x3b3;A7, PCDH&#x3b3;A9, PCDHG&#x3b2;5, PCDH&#x3b2;9</td>
<td valign="top" align="left">Involved in cell adhesion</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Overall, amongst the 103 genes in common between the brain and spinal cord of T cells recipient mice with demyelination (<xref ref-type="fig" rid="f9">
<bold>Figures&#xa0;9</bold>
</xref>, <xref ref-type="fig" rid="f10">
<bold>10</bold>
</xref>), two pathways were identified that may have played a detrimental and regenerative role in CNS demyelination based on the literature. One is &#x201c;neuron projection extension involved in neuron projection guidance&#x201d; which was downregulated in T cell transferred groups, and another pathway is &#x201c;ensheathment of neurons&#x201d; which is upregulated in T cell transferred groups.</p>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<title>Discussion</title>
<p>Multiple sclerosis (MS) is a neurodegenerative disease that affects approximately 400,000 individuals in the United States with symptoms ranging from relatively benign to overwhelming (<xref ref-type="bibr" rid="B86">86</xref>, <xref ref-type="bibr" rid="B87">87</xref>). While the cause of MS remains elusive, it is generally thought that MS is an autoimmune disease, perhaps initiated by a viral infection, that attacks and degrades the myelin sheath (<xref ref-type="bibr" rid="B88">88</xref>). Numerous viruses have been proposed as causative agents. Various herpes viruses have been implicated as the trigger for an autoimmune response leading to MS, including HSV-1, HSV-2, HCMV, EBV, HHV-6, and HHV-7 (<xref ref-type="bibr" rid="B89">89</xref>&#x2013;<xref ref-type="bibr" rid="B91">91</xref>), although other studies dispute these findings (<xref ref-type="bibr" rid="B92">92</xref>, <xref ref-type="bibr" rid="B93">93</xref>). Many non-herpes viruses also have been implicated in MS. At present, the most widely used animal model for the study of MS is EAE. EAE is induced, usually in mice and rats, by immunization with adjuvant plus myelin or myelin components (<xref ref-type="bibr" rid="B94">94</xref>&#x2013;<xref ref-type="bibr" rid="B97">97</xref>). In addition to EAE, JC virus (JCV), Semiliki forest virus (SFV), human T lymphotropic virus (HTLV-1), Theiler&#x2019;s murine encephalomyelitis virus (TMEV), and mouse hepatitis virus (MHV) have all been used as experimental animal models of CNS demyelination (<xref ref-type="bibr" rid="B98">98</xref>&#x2013;<xref ref-type="bibr" rid="B104">104</xref>). The above animal models of MS are based on using either the viral model (<xref ref-type="bibr" rid="B105">105</xref>) or the direct autoimmune model (<xref ref-type="bibr" rid="B106">106</xref>) to initiate disease. The model of MS that we have developed in our Lab to study CNS demyelination incorporates both a viral and an immune component (<xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B43">43</xref>, <xref ref-type="bibr" rid="B73">73</xref>, <xref ref-type="bibr" rid="B107">107</xref>, <xref ref-type="bibr" rid="B108">108</xref>). In our model, neither HSV-1 nor IL-2 alone causes demyelination in mice. However, when we delivered IL-2 using the viral vector (HSV-IL-2), an MS-like pathology was observed in infected mice. Previously, we compared the HSV-IL-2 model of CNS demyelination with the MOG<sub>35&#x2013;55</sub>, MBP<sub>35&#x2013;47</sub>, and PLP<sub>190&#x2013;209</sub> models of EAE using standardized protocols and female C57BL/6 mice of the same age (<xref ref-type="bibr" rid="B73">73</xref>). In this study we have shown that mice with HSV-IL-2-induced and MOG-induced demyelinating diseases demonstrated a similar pattern and distribution of demyelination in their brain, spinal cord, and optic nerves, while no demyelination was detected in the optic nerves of MBP- and PLP-injected mice.</p>
<p>T cells are involved in CNS demyelination (<xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B24">24</xref>) and T<sub>H</sub>17 cells have also been shown to play a major role in many of the autoimmune diseases (<xref ref-type="bibr" rid="B48">48</xref>&#x2013;<xref ref-type="bibr" rid="B56">56</xref>, <xref ref-type="bibr" rid="B109">109</xref>). Thus, in this study we looked at the role of IL-17A in an HSV-IL-2 model of CNS demyelination. IL-17A has been implicated in the pathogenesis of many common autoimmune disorders, including MS, as well as rheumatoid arthritis (RA), psoriasis, and inflammatory bowel disease (<xref ref-type="bibr" rid="B48">48</xref>&#x2013;<xref ref-type="bibr" rid="B56">56</xref>). Similar to previous studies (<xref ref-type="bibr" rid="B48">48</xref>&#x2013;<xref ref-type="bibr" rid="B56">56</xref>), we have shown now that mice lacking the IL-17A gene are resistant to CNS pathology. The central importance of IL-17A in inflammatory conditions is illustrated by the recent approval of two monoclonal antibody therapies that inhibit interleukin-17A for treatment of psoriasis, spondyloarthropathies, psoriatic arthritis and ankylosing spondylitis (<xref ref-type="bibr" rid="B110">110</xref>), although both these antibody therapies have significant side effects. IL-17A is produced by many cell types including T cells, ILCs, CD4<sup>&#x2212;</sup>CD8<sup>&#x2212;</sup> T cells, &#x3b3;&#x3b4;T cells, invariant natural killer (iNK) T cells, NK cells, neutrophils, mast cells and B cells (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B29">29</xref>&#x2013;<xref ref-type="bibr" rid="B34">34</xref>). In this study we transferred T cells from IL-17A<sup>-/-</sup> mice to Rag<sup>-/-</sup> mice as well as T cells from WT mice to IL-17A<sup>-/-</sup> mice and showed both T cells and non-T cells are contributing to CNS demyelination. Among the non-T cells, we recently reported a primary role for ILC2 cells but not ILC1 or ILC3 in our model of CNS demyelination (<xref ref-type="bibr" rid="B111">111</xref>). In this study we have shown that the absence of ILC2 blocked CNS demyelination in infected mice. Thus, our current study and our previous study (<xref ref-type="bibr" rid="B111">111</xref>) suggests that T cells and ILC2 producing IL-17A are contributing to CNS demyelination.</p>
<p>The IL-17 family of cytokines in both mice and human contains five members of the IL-17 receptor (IL-17R) family&#x2014;IL-17RA, IL-17RB, IL-17RC, IL-17RD, and IL-17RE (<xref ref-type="bibr" rid="B57">57</xref>, <xref ref-type="bibr" rid="B58">58</xref>). IL-17A and IL-17F both bind to IL-17 receptors A (IL-17RA) and C (IL-17RC), whose engagement activates mitogen-activated protein kinases (MAPKs), nuclear factor-kappa B (NF-&#x3ba;B), and CCAAT-enhancer-binding protein (C/EBP) signaling pathways through the adaptor proteins Act1 and TRAF6 (<xref ref-type="bibr" rid="B59">59</xref>, <xref ref-type="bibr" rid="B60">60</xref>). Thus, IL-17RC is an obligate co-receptor with IL-17RA for signaling induced by IL-17A and IL-17F. In addition, IL-17RC is required for IL-17A- and IL-17F-dependent signaling and has been implicated in the pathogenesis of EAE (<xref ref-type="bibr" rid="B61">61</xref>). In this study we looked at the role of IL-17RA, IL-17RC, and IL-17RD in CNS demyelination using a knockout for each gene. HSV-IL-2 infected IL-17RA<sup>-/-</sup>, IL-17RC<sup>-/-</sup>, or IL-17RD<sup>-/-</sup> mice all showed CNS demyelination, suggesting that other member of IL-17R compensate for the absence of the specific receptor. We also generated mice lacking both IL-17RA and IL-17RC, and the absence of both RA and RC did not block CNS demyelination. The severity of demyelination between different knockout mice lacking one or two of the receptor genes was not affected compared with WT infected mice. However, the functions of IL-17 receptors are not well characterized, and our results may suggest that the absence of all five receptors may be required to block CNS demyelination. Study is in progress to make a knockout mouse lacking all five receptor genes.</p>
<p>RNA-seq analysis further defined the role of IL-17A response against HSV-IL-2 induced demyelination. In our study we have shown the absence of CNS demyelination in IL-17A<sup>-/-</sup> mice following ocular infection with HSV-IL-2 virus, while transfer of T cells from WT mice to recipient IL-17A<sup>-/-</sup> mice caused CNS demyelination in infected mice. The transcriptome analysis in brains and spinal cords of infected IL-17A<sup>-/-</sup> mice with and without T cells transfer were compared after normalization with that of uninfected mice T cells. In both the brains and spinal cord of IL-17A<sup>-/-</sup> mice that received T cells transfer and demonstrated demyelination, 60 genes were upregulated, while 43 genes were downregulated. Based on the literature these genes are involved in both demyelination and remyelination. GO term analysis identified the two major pathways of &#x201c;neuron projection extension involved in neuron projection guidance&#x201d; which was downregulated in the T cell transferred group and &#x201c;ensheathment of neurons&#x201d; which is upregulated in T cell transferred group. These pathways are known to be involved in CNS demyelination in both MS and EAE models of MS (<xref ref-type="bibr" rid="B76">76</xref>&#x2013;<xref ref-type="bibr" rid="B85">85</xref>).</p>
<p>Our results have shown the importance of IL-17A in HSV-IL-2-induced CNS demyelination. Various molecules including TGF-&#x3b2;, IL-6, and IL-10 are contributing to the development of T<sub>H</sub>17 cells (<xref ref-type="bibr" rid="B60">60</xref>, <xref ref-type="bibr" rid="B62">62</xref>). At the same time, the absence of these three cytokines can result in the generation of pathogenic T<sub>H</sub>17 cells (<xref ref-type="bibr" rid="B63">63</xref>, <xref ref-type="bibr" rid="B64">64</xref>). In this current study, the lack of IL-6 or IL-10 and the absence of TGF-&#x3b2; expression in DCs or T cells did not alter the level of demyelination in the CNS of infected mice. Overall, our results suggest that IL-6, IL-10 or TGF-&#x3b2; are not required for T<sub>H</sub>17 cell induced demyelination and expression of IL-2 by HSV-IL-2 plays an important role in the generation of pathogenic T<sub>H</sub>17 cells as was reported previously (<xref ref-type="bibr" rid="B28">28</xref>).</p>
</sec>
<sec id="s5" sec-type="data-availability">
<title>Data availability statement</title>
<p>The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: GSE219020 (GEO).</p>
</sec>
<sec id="s6" sec-type="ethics-statement">
<title>Ethics statement</title>
<p>The animal research protocols were approved by the Institutional Animal Care and Use Committee of Cedars-Sinai Medical Center (Protocols # 6134 and 9833).</p>
</sec>
<sec id="s7" sec-type="author-contributions">
<title>Author contributions</title>
<p>SH and HG conceived the studies. SH, SW and HM performed experiments and generated primary data, including developing methodology, validation, and data curation. SH, SW, HM and HG performed formal analysis and visualization. SH, SW, SM-K and RL assisted in animal colony maintenance and performing mouse experiments. SW and SH performed and analyzed transcriptional profiling data. SH, UJ, SM-K and HG contributed to writing the manuscript. All authors contributed to reviewing and editing the final manuscript. HG was responsible for project supervision, administration, and funding acquisition. All authors contributed to the article and approved the submitted version.</p>
</sec>
</body>
<back>
<sec id="s8" sec-type="funding-information">
<title>Funding</title>
<p>This work was supported by Public Health Service grants RO1EY029677, RO1EY013615, and RO1EY026944.</p>
</sec>
<sec id="s9" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s10" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Margalit</surname> <given-names>E</given-names>
</name>
<name>
<surname>Sadda</surname> <given-names>SR</given-names>
</name>
</person-group>. <article-title>Retinal and optic nerve diseases</article-title>. <source>Artif Organs</source> (<year>2003</year>) <volume>27</volume>:<page-range>963&#x2013;74</page-range>. doi: <pub-id pub-id-type="doi">10.1046/j.1525-1594.2003.07304.x</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soderstrom</surname> <given-names>M</given-names>
</name>
<name>
<surname>Ya-Ping</surname> <given-names>J</given-names>
</name>
<name>
<surname>Hillert</surname> <given-names>J</given-names>
</name>
<name>
<surname>Link</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Optic neuritis: Prognosis for multiple sclerosis from MRI, CSF, and HLA findings</article-title>. <source>Neurology</source> (<year>1998</year>) <volume>50</volume>:<page-range>708&#x2013;14</page-range>. doi: <pub-id pub-id-type="doi">10.1212/WNL.50.3.708</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghezzi</surname> <given-names>A</given-names>
</name>
<name>
<surname>Martinelli</surname> <given-names>V</given-names>
</name>
<name>
<surname>Torri</surname> <given-names>V</given-names>
</name>
<name>
<surname>Zaffaroni</surname> <given-names>M</given-names>
</name>
<name>
<surname>Rodegher</surname> <given-names>M</given-names>
</name>
<name>
<surname>Comi</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Long-term follow-up of isolated optic neuritis: The risk of developing multiple sclerosis, its outcome, and the prognostic role of paraclinical tests</article-title>. <source>J Neurol</source> (<year>1999</year>) <volume>246</volume>:<page-range>770&#x2013;5</page-range>. doi: <pub-id pub-id-type="doi">10.1007/s004150050453</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Challoner</surname> <given-names>PB</given-names>
</name>
<name>
<surname>Smith</surname> <given-names>KT</given-names>
</name>
<name>
<surname>Parker</surname> <given-names>JD</given-names>
</name>
<name>
<surname>MacLeod</surname> <given-names>DL</given-names>
</name>
<name>
<surname>Coulter</surname> <given-names>SN</given-names>
</name>
<name>
<surname>Rose</surname> <given-names>TM</given-names>
</name>
<etal/>
</person-group>. <article-title>Plaque-associated expression of human herpesvirus 6 in multiple sclerosis</article-title>. <source>Proc Natl Acad Sci U.S.A.</source> (<year>1995</year>) <volume>92</volume>:<page-range>7440&#x2013;4</page-range>. doi: <pub-id pub-id-type="doi">10.1073/pnas.92.16.7440</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Friedman</surname> <given-names>JE</given-names>
</name>
<name>
<surname>Lyons</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Cu</surname> <given-names>G</given-names>
</name>
<name>
<surname>Ablashl</surname> <given-names>DV</given-names>
</name>
<name>
<surname>Whitman</surname> <given-names>JE</given-names>
</name>
<name>
<surname>Edgar</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>The association of the human herpesvirus-6 and MS</article-title>. <source>Mult Scler</source> (<year>1999</year>) <volume>5</volume>:<page-range>355&#x2013;62</page-range>. doi: <pub-id pub-id-type="doi">10.1177/135245859900500509</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boman</surname> <given-names>J</given-names>
</name>
<name>
<surname>Roblin</surname> <given-names>PM</given-names>
</name>
<name>
<surname>Sundstrom</surname> <given-names>P</given-names>
</name>
<name>
<surname>Sandstrom</surname> <given-names>M</given-names>
</name>
<name>
<surname>Hammerschlag</surname> <given-names>MR</given-names>
</name>
</person-group>. <article-title>Failure to detect chlamydia pneumoniae in the central nervous system of patients with MS</article-title>. <source>Neurology</source> (<year>2000</year>) <volume>54</volume>:<fpage>265</fpage>. doi: <pub-id pub-id-type="doi">10.1212/WNL.54.1.265</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martin</surname> <given-names>C</given-names>
</name>
<name>
<surname>Enbom</surname> <given-names>M</given-names>
</name>
<name>
<surname>Soderstrom</surname> <given-names>M</given-names>
</name>
<name>
<surname>Fredrikson</surname> <given-names>S</given-names>
</name>
<name>
<surname>Dahl</surname> <given-names>H</given-names>
</name>
<name>
<surname>Lycke</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Absence of seven human herpesviruses, including HHV-6, by polymerase chain reaction in CSF and blood from patients with multiple sclerosis and optic neuritis</article-title>. <source>Acta Neurol Scand</source> (<year>1997</year>) <volume>95</volume>:<page-range>280&#x2013;3</page-range>. doi: <pub-id pub-id-type="doi">10.1111/j.1600-0404.1997.tb00210.x</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mirandola</surname> <given-names>P</given-names>
</name>
<name>
<surname>Stefan</surname> <given-names>A</given-names>
</name>
<name>
<surname>Brambilla</surname> <given-names>E</given-names>
</name>
<name>
<surname>Campadelli-Fiume</surname> <given-names>G</given-names>
</name>
<name>
<surname>Grimaldi</surname> <given-names>LM</given-names>
</name>
</person-group>. <article-title>Absence of human herpesvirus 6 and 7 from spinal fluid and serum of multiple sclerosis patients</article-title>. <source>Neurology</source> (<year>1999</year>) <volume>53</volume>:<page-range>1367&#x2013;8</page-range>. doi: <pub-id pub-id-type="doi">10.1212/WNL.53.6.1367-a</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barnes</surname> <given-names>D</given-names>
</name>
<name>
<surname>McDonald</surname> <given-names>WI</given-names>
</name>
</person-group>. <article-title>The ocular manifestations of multiple sclerosis. 2. abnormalities of eye movements</article-title>. <source>J Neurol Neurosurg Psychiatry</source> (<year>1992</year>) <volume>55</volume>:<page-range>863&#x2013;8</page-range>. doi: <pub-id pub-id-type="doi">10.1136/jnnp.55.10.863</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McDonald</surname> <given-names>WI</given-names>
</name>
<name>
<surname>Barnes</surname> <given-names>D</given-names>
</name>
</person-group>. <article-title>The ocular manifestations of multiple sclerosis. 1. abnormalities of the afferent visual system</article-title>. <source>J Neurol Neurosurg Psychiatry</source> (<year>1992</year>) <volume>55</volume>:<page-range>747&#x2013;52</page-range>. doi: <pub-id pub-id-type="doi">10.1136/jnnp.55.9.747</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beck</surname> <given-names>RW</given-names>
</name>
<name>
<surname>Cleary</surname> <given-names>PA</given-names>
</name>
<name>
<surname>Anderson</surname> <given-names>MM</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Keltner</surname> <given-names>JL</given-names>
</name>
<name>
<surname>Shults</surname> <given-names>WT</given-names>
</name>
<name>
<surname>Kaufman</surname> <given-names>DI</given-names>
</name>
<etal/>
</person-group>. <article-title>A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. the optic neuritis study group</article-title>. <source>N Engl J Med</source> (<year>1992</year>) <volume>326</volume>:<page-range>581&#x2013;8</page-range>. doi: <pub-id pub-id-type="doi">10.1056/NEJM199202273260901</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rao</surname> <given-names>NA</given-names>
</name>
<name>
<surname>Guy</surname> <given-names>J</given-names>
</name>
<name>
<surname>Sheffield</surname> <given-names>PS</given-names>
</name>
</person-group>. <article-title>Effects of chronic demyelination on axonal transport in experimental allergic optic neuritis</article-title>. <source>Invest Ophthalmol Vis Sci</source> (<year>1981</year>) <volume>21</volume>:<page-range>606&#x2013;11</page-range>.</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rizzo</surname> <given-names>JF</given-names>
<suffix>3rd</suffix>
</name>
<name>
<surname>Lessell</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Risk of developing multiple sclerosis after uncomplicated optic neuritis: A long-term prospective study</article-title>. <source>Neurology</source> (<year>1988</year>) <volume>38</volume>:<page-range>185&#x2013;90</page-range>. doi: <pub-id pub-id-type="doi">10.1212/WNL.38.2.185</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beck</surname> <given-names>RW</given-names>
</name>
<name>
<surname>Trobe</surname> <given-names>JD</given-names>
</name>
<name>
<surname>Moke</surname> <given-names>PS</given-names>
</name>
<name>
<surname>Gal</surname> <given-names>RL</given-names>
</name>
<name>
<surname>Xing</surname> <given-names>D</given-names>
</name>
<name>
<surname>Bhatti</surname> <given-names>MT</given-names>
</name>
<etal/>
</person-group>. <article-title>High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: Experience of the optic neuritis treatment trial</article-title>. <source>Arch Ophthalmol</source> (<year>2003</year>) <volume>121</volume>:<page-range>944&#x2013;9</page-range>. doi: <pub-id pub-id-type="doi">10.1001/archopht.121.7.944</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Volpe</surname> <given-names>NJ</given-names>
</name>
</person-group>. <article-title>The optic neuritis treatment trial: A definitive answer and profound impact with unexpected results</article-title>. <source>Arch Ophthalmol</source> (<year>2008</year>) <volume>126</volume>:<page-range>996&#x2013;9</page-range>. doi: <pub-id pub-id-type="doi">10.1001/archopht.126.7.996</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sandberg-Wollheim</surname> <given-names>M</given-names>
</name>
<name>
<surname>Bynke</surname> <given-names>H</given-names>
</name>
<name>
<surname>Cronqvist</surname> <given-names>S</given-names>
</name>
<name>
<surname>Holtas</surname> <given-names>S</given-names>
</name>
<name>
<surname>Platz</surname> <given-names>P</given-names>
</name>
<name>
<surname>Ryder</surname> <given-names>LP</given-names>
</name>
</person-group>. <article-title>A long-term prospective study of optic neuritis: evaluation of risk factors</article-title>. <source>Ann Neurol</source> (<year>1990</year>) <volume>27</volume>:<page-range>386&#x2013;93</page-range>. doi: <pub-id pub-id-type="doi">10.1002/ana.410270406</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodriguez</surname> <given-names>M</given-names>
</name>
<name>
<surname>Siva</surname> <given-names>A</given-names>
</name>
<name>
<surname>Cross</surname> <given-names>SA</given-names>
</name>
<name>
<surname>O&#x2019;Brien</surname> <given-names>PC</given-names>
</name>
<name>
<surname>Kurland</surname> <given-names>LT</given-names>
</name>
</person-group>. <article-title>Optic neuritis: a population-based study in Olmsted county, Minnesota</article-title>. <source>Neurology</source> (<year>1995</year>) <volume>45</volume>:<page-range>244&#x2013;50</page-range>. doi: <pub-id pub-id-type="doi">10.1212/WNL.45.2.244</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>O&#x2019;Riordan</surname> <given-names>JI</given-names>
</name>
<name>
<surname>Losseff</surname> <given-names>NA</given-names>
</name>
<name>
<surname>Phatouros</surname> <given-names>C</given-names>
</name>
<name>
<surname>Thompson</surname> <given-names>AJ</given-names>
</name>
<name>
<surname>Moseley</surname> <given-names>IF</given-names>
</name>
<name>
<surname>MacManus</surname> <given-names>DG</given-names>
</name>
<etal/>
</person-group>. <article-title>Asymptomatic spinal cord lesions in clinically isolated optic nerve, brain stem, and spinal cord syndromes suggestive of demyelination</article-title>. <source>J Neurol Neurosurg Psychiatry</source> (<year>1998</year>) <volume>64</volume>:<page-range>353&#x2013;7</page-range>. doi: <pub-id pub-id-type="doi">10.1136/jnnp.64.3.353</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghiasi</surname> <given-names>H</given-names>
</name>
<name>
<surname>Osorio</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Perng</surname> <given-names>GC</given-names>
</name>
<name>
<surname>Nesburn</surname> <given-names>AB</given-names>
</name>
<name>
<surname>Wechsler</surname> <given-names>SL</given-names>
</name>
</person-group>. <article-title>Overexpression of interleukin-2 by a recombinant herpes simplex virus type 1 attenuates pathogenicity and enhances antiviral immunity</article-title>. <source>J Virol</source> (<year>2002</year>) <volume>76</volume>:<page-range>9069&#x2013;78</page-range>. doi: <pub-id pub-id-type="doi">10.1128/JVI.76.18.9069-9078.2002</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Osorio</surname> <given-names>Y</given-names>
</name>
<name>
<surname>La Point</surname> <given-names>SF</given-names>
</name>
<name>
<surname>Nusinowitz</surname> <given-names>S</given-names>
</name>
<name>
<surname>Hofman</surname> <given-names>FM</given-names>
</name>
<name>
<surname>Ghiasi</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>CD8+-dependent CNS demyelination following ocular infection of mice with a recombinant HSV-1 expressing murine IL-2</article-title>. <source>Exp Neurol</source> (<year>2005</year>) <volume>193</volume>:<fpage>1</fpage>&#x2013;<lpage>18</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.expneurol.2004.12.004</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zandian</surname> <given-names>M</given-names>
</name>
<name>
<surname>Belisle</surname> <given-names>R</given-names>
</name>
<name>
<surname>Mott</surname> <given-names>KR</given-names>
</name>
<name>
<surname>Nusinowitz</surname> <given-names>S</given-names>
</name>
<name>
<surname>Hofman</surname> <given-names>FM</given-names>
</name>
<name>
<surname>Ghiasi</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Optic neuritis in different strains of mice by a recombinant HSV-1 expressing murine interleukin-2</article-title>. <source>Invest Ophthalmol Vis Sci</source> (<year>2009</year>) <volume>50</volume>:<page-range>3275&#x2013;82</page-range>. doi: <pub-id pub-id-type="doi">10.1167/iovs.08-3211</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghiasi</surname> <given-names>H</given-names>
</name>
<name>
<surname>Osorio</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Hedvat</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Perng</surname> <given-names>GC</given-names>
</name>
<name>
<surname>Nesburn</surname> <given-names>AB</given-names>
</name>
<name>
<surname>Wechsler</surname> <given-names>SL</given-names>
</name>
</person-group>. <article-title>Infection of BALB/c mice with a herpes simplex virus type 1 recombinant virus expressing IFN-g driven by the LAT promoter</article-title>. <source>Virology</source> (<year>2002</year>) <volume>302</volume>:<page-range>144&#x2013;54</page-range>. doi: <pub-id pub-id-type="doi">10.1006/viro.2002.1609</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghiasi</surname> <given-names>H</given-names>
</name>
<name>
<surname>Osorio</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Perng</surname> <given-names>GC</given-names>
</name>
<name>
<surname>Nesburn</surname> <given-names>AB</given-names>
</name>
<name>
<surname>Wechsler</surname> <given-names>SL</given-names>
</name>
</person-group>. <article-title>Recombinant herpes simplex virus type 1 expressing murine interleukin-4 is less virulent than wild-type virus in mice</article-title>. <source>J Virol</source> (<year>2001</year>) <volume>75</volume>:<page-range>9029&#x2013;36</page-range>. doi: <pub-id pub-id-type="doi">10.1128/JVI.75.19.9029-9036.2001</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zandian</surname> <given-names>M</given-names>
</name>
<name>
<surname>Mott</surname> <given-names>KR</given-names>
</name>
<name>
<surname>Allen</surname> <given-names>SJ</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>S</given-names>
</name>
<name>
<surname>Arditi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Ghiasi</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>IL-2 suppression of IL-12p70 by a a recombinant HSV-1 expressing IL-2 induces T cells auto-reactivity and CNS demyelination</article-title>. <source>PloS One</source> (<year>2011</year>) <volume>6</volume>:<fpage>e16820</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0016820</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname> <given-names>DH</given-names>
</name>
<name>
<surname>Zandian</surname> <given-names>M</given-names>
</name>
<name>
<surname>Kuo</surname> <given-names>J</given-names>
</name>
<name>
<surname>Mott</surname> <given-names>KR</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>S</given-names>
</name>
<name>
<surname>Arditi</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Suppression of IL-12p70 formation by IL-2 or following macrophage depletion causes T-cell autoreactivity leading to CNS demyelination in HSV-1-infected mice</article-title>. <source>PloS Pathog</source> (<year>2017</year>) <volume>13</volume>:<fpage>e1006401</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.ppat.1006401</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rizzo</surname> <given-names>HL</given-names>
</name>
<name>
<surname>Kagami</surname> <given-names>S</given-names>
</name>
<name>
<surname>Phillips</surname> <given-names>KG</given-names>
</name>
<name>
<surname>Kurtz</surname> <given-names>SE</given-names>
</name>
<name>
<surname>Jacques</surname> <given-names>SL</given-names>
</name>
<name>
<surname>Blauvelt</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A</article-title>. <source>J Immunol</source> (<year>2011</year>) <volume>186</volume>:<page-range>1495&#x2013;502</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.1001001</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mudigonda</surname> <given-names>P</given-names>
</name>
<name>
<surname>Mudigonda</surname> <given-names>T</given-names>
</name>
<name>
<surname>Feneran</surname> <given-names>AN</given-names>
</name>
<name>
<surname>Alamdari</surname> <given-names>HS</given-names>
</name>
<name>
<surname>Sandoval</surname> <given-names>L</given-names>
</name>
<name>
<surname>Feldman</surname> <given-names>SR</given-names>
</name>
</person-group>. <article-title>Interleukin-23 and interleukin-17: Importance in pathogenesis and therapy of psoriasis</article-title>. <source>Dermatol Online J</source> (<year>2012</year>) <volume>18</volume>:<fpage>1</fpage>. doi: <pub-id pub-id-type="doi">10.5070/D33N39N8XM</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Haines</surname> <given-names>CJ</given-names>
</name>
<name>
<surname>Gutcher</surname> <given-names>I</given-names>
</name>
<name>
<surname>Hochweller</surname> <given-names>K</given-names>
</name>
<name>
<surname>Blumenschein</surname> <given-names>WM</given-names>
</name>
<name>
<surname>McClanahan</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Foxp3(+) regulatory T cells promote T helper 17 cell development <italic>in vivo</italic> through regulation of interleukin-2</article-title>. <source>Immunity</source> (<year>2011</year>) <volume>34</volume>:<page-range>409&#x2013;21</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2011.02.011</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crispin</surname> <given-names>JC</given-names>
</name>
<name>
<surname>Oukka</surname> <given-names>M</given-names>
</name>
<name>
<surname>Bayliss</surname> <given-names>G</given-names>
</name>
<name>
<surname>Cohen</surname> <given-names>RA</given-names>
</name>
<name>
<surname>Van Beek</surname> <given-names>CA</given-names>
</name>
<name>
<surname>Stillman</surname> <given-names>IE</given-names>
</name>
<etal/>
</person-group>. <article-title>Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys</article-title>. <source>J Immunol</source> (<year>2008</year>) <volume>181</volume>:<page-range>8761&#x2013;6</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.181.12.8761</pub-id>
</citation>
</ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sutton</surname> <given-names>CE</given-names>
</name>
<name>
<surname>Mielke</surname> <given-names>LA</given-names>
</name>
<name>
<surname>Mills</surname> <given-names>KH</given-names>
</name>
</person-group>. <article-title>IL-17-producing gammadelta T cells and innate lymphoid cells</article-title>. <source>Eur J Immunol</source> (<year>2012</year>) <volume>42</volume>:<page-range>2221&#x2013;31</page-range>. doi: <pub-id pub-id-type="doi">10.1002/eji.201242569</pub-id>
</citation>
</ref>
<ref id="B31">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cua</surname> <given-names>DJ</given-names>
</name>
<name>
<surname>Tato</surname> <given-names>CM</given-names>
</name>
</person-group>. <article-title>Innate IL-17-producing cells: The sentinels of the immune system</article-title>. <source>Nat Rev Immunol</source> (<year>2010</year>) <volume>10</volume>:<page-range>479&#x2013;89</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nri2800</pub-id>
</citation>
</ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hueber</surname> <given-names>AJ</given-names>
</name>
<name>
<surname>Asquith</surname> <given-names>DL</given-names>
</name>
<name>
<surname>Miller</surname> <given-names>AM</given-names>
</name>
<name>
<surname>Reilly</surname> <given-names>J</given-names>
</name>
<name>
<surname>Kerr</surname> <given-names>S</given-names>
</name>
<name>
<surname>Leipe</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Mast cells express IL-17A in rheumatoid arthritis synovium</article-title>. <source>J Immunol</source> (<year>2010</year>) <volume>184</volume>:<page-range>3336&#x2013;40</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.0903566</pub-id>
</citation>
</ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papotto</surname> <given-names>PH</given-names>
</name>
<name>
<surname>Ribot</surname> <given-names>JC</given-names>
</name>
<name>
<surname>Silva-Santos</surname> <given-names>B</given-names>
</name>
</person-group>. <article-title>IL-17(+) gammadelta T cells as kick-starters of inflammation</article-title>. <source>Nat Immunol</source> (<year>2017</year>) <volume>18</volume>:<page-range>604&#x2013;11</page-range>. doi: <pub-id pub-id-type="doi">10.1038/ni.3726</pub-id>
</citation>
</ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leon</surname> <given-names>B</given-names>
</name>
<name>
<surname>Lund</surname> <given-names>FE</given-names>
</name>
</person-group>. <article-title>IL-17-producing b cells combat parasites</article-title>. <source>Nat Immunol</source> (<year>2013</year>) <volume>14</volume>:<page-range>419&#x2013;21</page-range>. doi: <pub-id pub-id-type="doi">10.1038/ni.2593</pub-id>
</citation>
</ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perng</surname> <given-names>GC</given-names>
</name>
<name>
<surname>Dunkel</surname> <given-names>EC</given-names>
</name>
<name>
<surname>Geary</surname> <given-names>PA</given-names>
</name>
<name>
<surname>Slanina</surname> <given-names>SM</given-names>
</name>
<name>
<surname>Ghiasi</surname> <given-names>H</given-names>
</name>
<name>
<surname>Kaiwar</surname> <given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>The latency-associated transcript gene of herpes simplex virus type 1 (HSV-1) is required for efficient <italic>in vivo</italic> spontaneous reactivation of HSV-1 from latency</article-title>. <source>J Virol</source> (<year>1994</year>) <volume>68</volume>:<page-range>8045&#x2013;55</page-range>. doi: <pub-id pub-id-type="doi">10.1128/jvi.68.12.8045-8055.1994</pub-id>
</citation>
</ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghiasi</surname> <given-names>H</given-names>
</name>
<name>
<surname>Kaiwar</surname> <given-names>R</given-names>
</name>
<name>
<surname>Nesburn</surname> <given-names>AB</given-names>
</name>
<name>
<surname>Slanina</surname> <given-names>S</given-names>
</name>
<name>
<surname>Wechsler</surname> <given-names>SL</given-names>
</name>
</person-group>. <article-title>Expression of seven herpes simplex virus type 1 glycoproteins (gB, gC, gD, gE, gG, gH, and gI): comparative protection against lethal challenge in mice</article-title>. <source>J Virol</source> (<year>1994</year>) <volume>68</volume>:<page-range>2118&#x2013;26</page-range>. doi: <pub-id pub-id-type="doi">10.1128/jvi.68.4.2118-2126.1994</pub-id>
</citation>
</ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghiasi</surname> <given-names>H</given-names>
</name>
<name>
<surname>Slanina</surname> <given-names>S</given-names>
</name>
<name>
<surname>Nesburn</surname> <given-names>AB</given-names>
</name>
<name>
<surname>Wechsler</surname> <given-names>SL</given-names>
</name>
</person-group>. <article-title>Characterization of baculovirus-expressed herpes simplex virus type 1 glycoprotein K</article-title>. <source>J Virol</source> (<year>1994</year>) <volume>68</volume>:<page-range>2347&#x2013;54</page-range>. doi: <pub-id pub-id-type="doi">10.1128/jvi.68.4.2347-2354.1994</pub-id>
</citation>
</ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laouar</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Sutterwala</surname> <given-names>FS</given-names>
</name>
<name>
<surname>Gorelik</surname> <given-names>L</given-names>
</name>
<name>
<surname>Flavell</surname> <given-names>RA</given-names>
</name>
</person-group>. <article-title>Transforming growth factor-beta controls T helper type 1 cell development through regulation of natural killer cell interferon-gamma</article-title>. <source>Nat Immunol</source> (<year>2005</year>) <volume>6</volume>:<page-range>600&#x2013;7</page-range>. doi: <pub-id pub-id-type="doi">10.1038/ni1197</pub-id>
</citation>
</ref>
<ref id="B39">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gorelik</surname> <given-names>L</given-names>
</name>
<name>
<surname>Flavell</surname> <given-names>RA</given-names>
</name>
</person-group>. <article-title>Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease</article-title>. <source>Immunity</source> (<year>2000</year>) <volume>12</volume>:<page-range>171&#x2013;81</page-range>. doi: <pub-id pub-id-type="doi">10.1016/S1074-7613(00)80170-3</pub-id>
</citation>
</ref>
<ref id="B40">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Allen</surname> <given-names>SJ</given-names>
</name>
<name>
<surname>Mott</surname> <given-names>KR</given-names>
</name>
<name>
<surname>Wechsler</surname> <given-names>SL</given-names>
</name>
<name>
<surname>Flavell</surname> <given-names>RA</given-names>
</name>
<name>
<surname>Town</surname> <given-names>T</given-names>
</name>
<name>
<surname>Ghiasi</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Adaptive and innate transforming growth factor beta signaling impact herpes simplex virus 1 latency and reactivation</article-title>. <source>J Virol</source> (<year>2011</year>) <volume>85</volume>:<page-range>11448&#x2013;56</page-range>. doi: <pub-id pub-id-type="doi">10.1128/JVI.00678-11</pub-id>
</citation>
</ref>
<ref id="B41">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hirose</surname> <given-names>S</given-names>
</name>
<name>
<surname>Jaggi</surname> <given-names>U</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>S</given-names>
</name>
<name>
<surname>Tormanen</surname> <given-names>K</given-names>
</name>
<name>
<surname>Nagaoka</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Katsumata</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Role of TH17 responses in increasing herpetic keratitis in the eyes of mice infected with HSV-1</article-title>. <source>Invest Ophthalmol Vis Sci</source> (<year>2020</year>) <volume>61</volume>:<fpage>20</fpage>. doi: <pub-id pub-id-type="doi">10.1167/iovs.61.6.20</pub-id>
</citation>
</ref>
<ref id="B42">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mott</surname> <given-names>KR</given-names>
</name>
<name>
<surname>Maazi</surname> <given-names>H</given-names>
</name>
<name>
<surname>Allen</surname> <given-names>SJ</given-names>
</name>
<name>
<surname>Zandian</surname> <given-names>M</given-names>
</name>
<name>
<surname>Matundan</surname> <given-names>H</given-names>
</name>
<name>
<surname>Ghiasi</surname> <given-names>YN</given-names>
</name>
<etal/>
</person-group>. <article-title>Batf3 deficiency is not critical for the generation of CD8alpha(+) dendritic cells</article-title>. <source>Immunobiology</source> (<year>2015</year>) <volume>220</volume>:<page-range>518&#x2013;24</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.imbio.2014.10.019</pub-id>
</citation>
</ref>
<ref id="B43">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zandian</surname> <given-names>M</given-names>
</name>
<name>
<surname>Mott</surname> <given-names>KR</given-names>
</name>
<name>
<surname>Allen</surname> <given-names>SJ</given-names>
</name>
<name>
<surname>Dumitrascu</surname> <given-names>O</given-names>
</name>
<name>
<surname>Kuo</surname> <given-names>JZ</given-names>
</name>
<name>
<surname>Ghiasi</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Use of cytokine immunotherapy to block CNS demyelination induced by a recombinant HSV-1 expressing murine interleukin-2</article-title>. <source>Gene Ther</source> (<year>2011</year>) <volume>18</volume>:<page-range>734&#x2013;42</page-range>. doi: <pub-id pub-id-type="doi">10.1038/gt.2011.32</pub-id>
</citation>
</ref>
<ref id="B44">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dobin</surname> <given-names>A</given-names>
</name>
<name>
<surname>Davis</surname> <given-names>CA</given-names>
</name>
<name>
<surname>Schlesinger</surname> <given-names>F</given-names>
</name>
<name>
<surname>Drenkow</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zaleski</surname> <given-names>C</given-names>
</name>
<name>
<surname>Jha</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>STAR: ultrafast universal RNA-seq aligner</article-title>. <source>Bioinformatics</source> (<year>2013</year>) <volume>29</volume>:<fpage>15</fpage>&#x2013;<lpage>21</lpage>. doi: <pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id>
</citation>
</ref>
<ref id="B45">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>B</given-names>
</name>
<name>
<surname>Dewey</surname> <given-names>CN</given-names>
</name>
</person-group>. <article-title>RSEM: accurate transcript quantification from RNA-seq data with or without a reference genome</article-title>. <source>BMC Bioinf</source> (<year>2011</year>) <volume>12</volume>:<fpage>323</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1471-2105-12-323</pub-id>
</citation>
</ref>
<ref id="B46">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Love</surname> <given-names>MI</given-names>
</name>
<name>
<surname>Huber</surname> <given-names>W</given-names>
</name>
<name>
<surname>Anders</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title>. <source>Genome Biol</source> (<year>2014</year>) <volume>15</volume>:<fpage>550</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id>
</citation>
</ref>
<ref id="B47">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname> <given-names>T</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>E</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>S</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>M</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>P</given-names>
</name>
<name>
<surname>Dai</surname> <given-names>Z</given-names>
</name>
<etal/>
</person-group>. <article-title>clusterProfiler 4.0: A universal enrichment tool for interpreting omics data</article-title>. <source>Innovation (Camb)</source> (<year>2021</year>) <volume>2</volume>:<fpage>100141</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.xinn.2021.100141</pub-id>
</citation>
</ref>
<ref id="B48">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lock</surname> <given-names>C</given-names>
</name>
<name>
<surname>Hermans</surname> <given-names>G</given-names>
</name>
<name>
<surname>Pedotti</surname> <given-names>R</given-names>
</name>
<name>
<surname>Brendolan</surname> <given-names>A</given-names>
</name>
<name>
<surname>Schadt</surname> <given-names>E</given-names>
</name>
<name>
<surname>Garren</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis</article-title>. <source>Nat Med</source> (<year>2002</year>) <volume>8</volume>:<page-range>500&#x2013;8</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nm0502-500</pub-id>
</citation>
</ref>
<ref id="B49">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cua</surname> <given-names>DJ</given-names>
</name>
<name>
<surname>Sherlock</surname> <given-names>J</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Murphy</surname> <given-names>CA</given-names>
</name>
<name>
<surname>Joyce</surname> <given-names>B</given-names>
</name>
<name>
<surname>Seymour</surname> <given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain</article-title>. <source>Nature</source> (<year>2003</year>) <volume>421</volume>:<page-range>744&#x2013;8</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nature01355</pub-id>
</citation>
</ref>
<ref id="B50">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fujino</surname> <given-names>S</given-names>
</name>
<name>
<surname>Andoh</surname> <given-names>A</given-names>
</name>
<name>
<surname>Bamba</surname> <given-names>S</given-names>
</name>
<name>
<surname>Ogawa</surname> <given-names>A</given-names>
</name>
<name>
<surname>Hata</surname> <given-names>K</given-names>
</name>
<name>
<surname>Araki</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Increased expression of interleukin 17 in inflammatory bowel disease</article-title>. <source>Gut</source> (<year>2003</year>) <volume>52</volume>:<fpage>65</fpage>&#x2013;<lpage>70</lpage>. doi: <pub-id pub-id-type="doi">10.1136/gut.52.1.65</pub-id>
</citation>
</ref>
<ref id="B51">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Langrish</surname> <given-names>CL</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Blumenschein</surname> <given-names>WM</given-names>
</name>
<name>
<surname>Mattson</surname> <given-names>J</given-names>
</name>
<name>
<surname>Basham</surname> <given-names>B</given-names>
</name>
<name>
<surname>Sedgwick</surname> <given-names>JD</given-names>
</name>
<etal/>
</person-group>. <article-title>IL-23 drives a pathogenic T cell population that induces autoimmune inflammation</article-title>. <source>J Exp Med</source> (<year>2005</year>) <volume>201</volume>:<page-range>233&#x2013;40</page-range>. doi: <pub-id pub-id-type="doi">10.1084/jem.20041257</pub-id>
</citation>
</ref>
<ref id="B52">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilson</surname> <given-names>NJ</given-names>
</name>
<name>
<surname>Boniface</surname> <given-names>K</given-names>
</name>
<name>
<surname>Chan</surname> <given-names>JR</given-names>
</name>
<name>
<surname>McKenzie</surname> <given-names>BS</given-names>
</name>
<name>
<surname>Blumenschein</surname> <given-names>WM</given-names>
</name>
<name>
<surname>Mattson</surname> <given-names>JD</given-names>
</name>
<etal/>
</person-group>. <article-title>Development, cytokine profile and function of human interleukin 17-producing helper T cells</article-title>. <source>Nat Immunol</source> (<year>2007</year>) <volume>8</volume>:<page-range>950&#x2013;7</page-range>. doi: <pub-id pub-id-type="doi">10.1038/ni1497</pub-id>
</citation>
</ref>
<ref id="B53">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Korn</surname> <given-names>T</given-names>
</name>
<name>
<surname>Bettelli</surname> <given-names>E</given-names>
</name>
<name>
<surname>Oukka</surname> <given-names>M</given-names>
</name>
<name>
<surname>Kuchroo</surname> <given-names>VK</given-names>
</name>
</person-group>. <article-title>IL-17 and Th17 cells</article-title>. <source>Annu Rev Immunol</source> (<year>2009</year>) <volume>27</volume>:<fpage>485</fpage>&#x2013;<lpage>517</lpage>. doi: <pub-id pub-id-type="doi">10.1146/annurev.immunol.021908.132710</pub-id>
</citation>
</ref>
<ref id="B54">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fletcher</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Lalor</surname> <given-names>SJ</given-names>
</name>
<name>
<surname>Sweeney</surname> <given-names>CM</given-names>
</name>
<name>
<surname>Tubridy</surname> <given-names>N</given-names>
</name>
<name>
<surname>Mills</surname> <given-names>KH</given-names>
</name>
</person-group>. <article-title>T Cells in multiple sclerosis and experimental autoimmune encephalomyelitis</article-title>. <source>Clin Exp Immunol</source> (<year>2010</year>) <volume>162</volume>:<fpage>1</fpage>&#x2013;<lpage>11</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1365-2249.2010.04143.x</pub-id>
</citation>
</ref>
<ref id="B55">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname> <given-names>HJ</given-names>
</name>
<name>
<surname>Yuk</surname> <given-names>CM</given-names>
</name>
<name>
<surname>Shin</surname> <given-names>K</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>SH</given-names>
</name>
</person-group>. <article-title>Interleukin-17A negatively regulates lymphangiogenesis in T helper 17 cell-mediated inflammation</article-title>. <source>Mucosal Immunol</source> (<year>2017</year>) <volume>11</volume>:<page-range>590&#x2013;600</page-range>. doi: <pub-id pub-id-type="doi">10.1038/mi.2017.76</pub-id>
</citation>
</ref>
<ref id="B56">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ouyang</surname> <given-names>W</given-names>
</name>
<name>
<surname>Kolls</surname> <given-names>JK</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>Y</given-names>
</name>
</person-group>. <article-title>The biological functions of T helper 17 cell effector cytokines in inflammation</article-title>. <source>Immunity</source> (<year>2008</year>) <volume>28</volume>:<page-range>454&#x2013;67</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2008.03.004</pub-id>
</citation>
</ref>
<ref id="B57">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kolls</surname> <given-names>JK</given-names>
</name>
<name>
<surname>Linden</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Interleukin-17 family members and inflammation</article-title>. <source>Immunity</source> (<year>2004</year>) <volume>21</volume>:<page-range>467&#x2013;76</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2004.08.018</pub-id>
</citation>
</ref>
<ref id="B58">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moseley</surname> <given-names>TA</given-names>
</name>
<name>
<surname>Haudenschild</surname> <given-names>DR</given-names>
</name>
<name>
<surname>Rose</surname> <given-names>L</given-names>
</name>
<name>
<surname>Reddi</surname> <given-names>AH</given-names>
</name>
</person-group>. <article-title>Interleukin-17 family and IL-17 receptors</article-title>. <source>Cytokine Growth Factor Rev</source> (<year>2003</year>) <volume>14</volume>:<page-range>155&#x2013;74</page-range>. doi: <pub-id pub-id-type="doi">10.1016/S1359-6101(03)00002-9</pub-id>
</citation>
</ref>
<ref id="B59">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iwakura</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Ishigame</surname> <given-names>H</given-names>
</name>
<name>
<surname>Saijo</surname> <given-names>S</given-names>
</name>
<name>
<surname>Nakae</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Functional specialization of interleukin-17 family members</article-title>. <source>Immunity</source> (<year>2011</year>) <volume>34</volume>:<page-range>149&#x2013;62</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2011.02.012</pub-id>
</citation>
</ref>
<ref id="B60">
<label>60</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reynolds</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Angkasekwinai</surname> <given-names>P</given-names>
</name>
<name>
<surname>Dong</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>IL-17 family member cytokines: regulation and function in innate immunity</article-title>. <source>Cytokine Growth Factor Rev</source> (<year>2010</year>) <volume>21</volume>:<page-range>413&#x2013;23</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.cytogfr.2010.10.002</pub-id>
</citation>
</ref>
<ref id="B61">
<label>61</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Ota</surname> <given-names>N</given-names>
</name>
<name>
<surname>Peng</surname> <given-names>I</given-names>
</name>
<name>
<surname>Refino</surname> <given-names>CJ</given-names>
</name>
<name>
<surname>Danilenko</surname> <given-names>DM</given-names>
</name>
<name>
<surname>Caplazi</surname> <given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>IL-17RC is required for IL-17A- and IL-17F-dependent signaling and the pathogenesis of experimental autoimmune encephalomyelitis</article-title>. <source>J Immunol</source> (<year>2010</year>) <volume>184</volume>:<page-range>4307&#x2013;16</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.0903614</pub-id>
</citation>
</ref>
<ref id="B62">
<label>62</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stockinger</surname> <given-names>B</given-names>
</name>
<name>
<surname>Omenetti</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>The dichotomous nature of T helper 17 cells</article-title>. <source>Nat Rev Immunol</source> (<year>2017</year>) <volume>17</volume>:<page-range>535&#x2013;44</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nri.2017.50</pub-id>
</citation>
</ref>
<ref id="B63">
<label>63</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghoreschi</surname> <given-names>K</given-names>
</name>
<name>
<surname>Laurence</surname> <given-names>A</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>XP</given-names>
</name>
<name>
<surname>Tato</surname> <given-names>CM</given-names>
</name>
<name>
<surname>McGeachy</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Konkel</surname> <given-names>JE</given-names>
</name>
<etal/>
</person-group>. <article-title>Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling</article-title>. <source>Nature</source> (<year>2010</year>) <volume>467</volume>:<page-range>967&#x2013;71</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nature09447</pub-id>
</citation>
</ref>
<ref id="B64">
<label>64</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McGeachy</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Bak-Jensen</surname> <given-names>KS</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Tato</surname> <given-names>CM</given-names>
</name>
<name>
<surname>Blumenschein</surname> <given-names>W</given-names>
</name>
<name>
<surname>McClanahan</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology</article-title>. <source>Nat Immunol</source> (<year>2007</year>) <volume>8</volume>:<page-range>1390&#x2013;7</page-range>. doi: <pub-id pub-id-type="doi">10.1038/ni1539</pub-id>
</citation>
</ref>
<ref id="B65">
<label>65</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname> <given-names>L</given-names>
</name>
<name>
<surname>Chong</surname> <given-names>MM</given-names>
</name>
<name>
<surname>Littman</surname> <given-names>DR</given-names>
</name>
</person-group>. <article-title>Plasticity of CD4+ T cell lineage differentiation</article-title>. <source>Immunity</source> (<year>2009</year>) <volume>30</volume>:<page-range>646&#x2013;55</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2009.05.001</pub-id>
</citation>
</ref>
<ref id="B66">
<label>66</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dunker</surname> <given-names>N</given-names>
</name>
<name>
<surname>Krieglstein</surname> <given-names>K</given-names>
</name>
</person-group>. <article-title>Targeted mutations of transforming growth factor-beta genes reveal important roles in mouse development and adult homeostasis</article-title>. <source>Eur J Biochem</source> (<year>2000</year>) <volume>267</volume>:<page-range>6982&#x2013;8</page-range>. doi: <pub-id pub-id-type="doi">10.1046/j.1432-1327.2000.01825.x</pub-id>
</citation>
</ref>
<ref id="B67">
<label>67</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wahl</surname> <given-names>SM</given-names>
</name>
</person-group>. <article-title>Transforming growth factor-beta: innately bipolar</article-title>. <source>Curr Opin Immunol</source> (<year>2007</year>) <volume>19</volume>:<fpage>55</fpage>&#x2013;<lpage>62</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.coi.2006.11.008</pub-id>
</citation>
</ref>
<ref id="B68">
<label>68</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wahl</surname> <given-names>SM</given-names>
</name>
<name>
<surname>Wen</surname> <given-names>J</given-names>
</name>
<name>
<surname>Moutsopoulos</surname> <given-names>N</given-names>
</name>
</person-group>. <article-title>TGF-beta: a mobile purveyor of immune privilege</article-title>. <source>Immunol Rev</source> (<year>2006</year>) <volume>213</volume>:<page-range>213&#x2013;27</page-range>. doi: <pub-id pub-id-type="doi">10.1111/j.1600-065X.2006.00437.x</pub-id>
</citation>
</ref>
<ref id="B69">
<label>69</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kulkarni</surname> <given-names>AB</given-names>
</name>
<name>
<surname>Huh</surname> <given-names>CG</given-names>
</name>
<name>
<surname>Becker</surname> <given-names>D</given-names>
</name>
<name>
<surname>Geiser</surname> <given-names>A</given-names>
</name>
<name>
<surname>Lyght</surname> <given-names>M</given-names>
</name>
<name>
<surname>Flanders</surname> <given-names>KC</given-names>
</name>
<etal/>
</person-group>. <article-title>Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death</article-title>. <source>Proc Natl Acad Sci U.S.A.</source> (<year>1993</year>) <volume>90</volume>:<page-range>770&#x2013;4</page-range>. doi: <pub-id pub-id-type="doi">10.1073/pnas.90.2.770</pub-id>
</citation>
</ref>
<ref id="B70">
<label>70</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaartinen</surname> <given-names>V</given-names>
</name>
<name>
<surname>Voncken</surname> <given-names>JW</given-names>
</name>
<name>
<surname>Shuler</surname> <given-names>C</given-names>
</name>
<name>
<surname>Warburton</surname> <given-names>D</given-names>
</name>
<name>
<surname>Bu</surname> <given-names>D</given-names>
</name>
<name>
<surname>Heisterkamp</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Abnormal lung development and cleft palate in mice lacking TGF-beta 3 indicates defects of epithelial-mesenchymal interaction</article-title>. <source>Nat Genet</source> (<year>1995</year>) <volume>11</volume>:<page-range>415&#x2013;21</page-range>. doi: <pub-id pub-id-type="doi">10.1038/ng1295-415</pub-id>
</citation>
</ref>
<ref id="B71">
<label>71</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Proetzel</surname> <given-names>G</given-names>
</name>
<name>
<surname>Pawlowski</surname> <given-names>SA</given-names>
</name>
<name>
<surname>Wiles</surname> <given-names>MV</given-names>
</name>
<name>
<surname>Yin</surname> <given-names>M</given-names>
</name>
<name>
<surname>Boivin</surname> <given-names>GP</given-names>
</name>
<name>
<surname>Howles</surname> <given-names>PN</given-names>
</name>
<etal/>
</person-group>. <article-title>Transforming growth factor-beta 3 is required for secondary palate fusion</article-title>. <source>Nat Genet</source> (<year>1995</year>) <volume>11</volume>:<page-range>409&#x2013;14</page-range>. doi: <pub-id pub-id-type="doi">10.1038/ng1295-409</pub-id>
</citation>
</ref>
<ref id="B72">
<label>72</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanford</surname> <given-names>LP</given-names>
</name>
<name>
<surname>Ormsby</surname> <given-names>I</given-names>
</name>
<name>
<surname>Gittenberger-de Groot</surname> <given-names>AC</given-names>
</name>
<name>
<surname>Sariola</surname> <given-names>H</given-names>
</name>
<name>
<surname>Friedman</surname> <given-names>R</given-names>
</name>
<name>
<surname>Boivin</surname> <given-names>GP</given-names>
</name>
<etal/>
</person-group>. <article-title>TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes</article-title>. <source>Development</source> (<year>1997</year>) <volume>124</volume>:<page-range>2659&#x2013;70</page-range>. doi: <pub-id pub-id-type="doi">10.1242/dev.124.13.2659</pub-id>
</citation>
</ref>
<ref id="B73">
<label>73</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dumitrascu</surname> <given-names>OM</given-names>
</name>
<name>
<surname>Mott</surname> <given-names>KR</given-names>
</name>
<name>
<surname>Ghiasi</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>A comparative study of experimental mouse models of central nervous system demyelination</article-title>. <source>Gene Ther</source> (<year>2014</year>) <volume>21</volume>:<fpage>599</fpage>&#x2013;<lpage>608</lpage>. doi: <pub-id pub-id-type="doi">10.1038/gt.2014.33</pub-id>
</citation>
</ref>
<ref id="B74">
<label>74</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jahn</surname> <given-names>O</given-names>
</name>
<name>
<surname>Siems</surname> <given-names>SB</given-names>
</name>
<name>
<surname>Kusch</surname> <given-names>K</given-names>
</name>
<name>
<surname>Hesse</surname> <given-names>D</given-names>
</name>
<name>
<surname>Jung</surname> <given-names>RB</given-names>
</name>
<name>
<surname>Liepold</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>The CNS myelin proteome: Deep profile and persistence after post-mortem delay</article-title>. <source>Front Cell Neurosci</source> (<year>2020</year>) <volume>14</volume>:<elocation-id>239</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fncel.2020.00239</pub-id>
</citation>
</ref>
<ref id="B75">
<label>75</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sospedra</surname> <given-names>M</given-names>
</name>
<name>
<surname>Martin</surname> <given-names>R</given-names>
</name>
</person-group>. <article-title>Immunology of multiple sclerosis</article-title>. <source>Annu Rev Immunol</source> (<year>2005</year>) <volume>23</volume>:<fpage>683</fpage>&#x2013;<lpage>747</lpage>. doi: <pub-id pub-id-type="doi">10.1146/annurev.immunol.23.021704.115707</pub-id>
</citation>
</ref>
<ref id="B76">
<label>76</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ypsilanti</surname> <given-names>AR</given-names>
</name>
<name>
<surname>Zagar</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Chedotal</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Moving away from the midline: new developments for slit and robo</article-title>. <source>Development</source> (<year>2010</year>) <volume>137</volume>:<page-range>1939&#x2013;52</page-range>. doi: <pub-id pub-id-type="doi">10.1242/dev.044511</pub-id>
</citation>
</ref>
<ref id="B77">
<label>77</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pasterkamp</surname> <given-names>RJ</given-names>
</name>
</person-group>. <article-title>Getting neural circuits into shape with semaphorins</article-title>. <source>Nat Rev Neurosci</source> (<year>2012</year>) <volume>13</volume>:<page-range>605&#x2013;18</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nrn3302</pub-id>
</citation>
</ref>
<ref id="B78">
<label>78</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Flaherty</surname> <given-names>E</given-names>
</name>
<name>
<surname>Maniatis</surname> <given-names>T</given-names>
</name>
</person-group>. <article-title>The role of clustered protocadherins in neurodevelopment and neuropsychiatric diseases</article-title>. <source>Curr Opin Genet Dev</source> (<year>2020</year>) <volume>65</volume>:<page-range>144&#x2013;50</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.gde.2020.05.041</pub-id>
</citation>
</ref>
<ref id="B79">
<label>79</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Michailidou</surname> <given-names>I</given-names>
</name>
<name>
<surname>Willems</surname> <given-names>JG</given-names>
</name>
<name>
<surname>Kooi</surname> <given-names>EJ</given-names>
</name>
<name>
<surname>van Eden</surname> <given-names>C</given-names>
</name>
<name>
<surname>Gold</surname> <given-names>SM</given-names>
</name>
<name>
<surname>Geurts</surname> <given-names>JJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Complement C1q-C3-associated synaptic changes in multiple sclerosis hippocampus</article-title>. <source>Ann Neurol</source> (<year>2015</year>) <volume>77</volume>:<page-range>1007&#x2013;26</page-range>. doi: <pub-id pub-id-type="doi">10.1002/ana.24398</pub-id>
</citation>
</ref>
<ref id="B80">
<label>80</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Piaton</surname> <given-names>G</given-names>
</name>
<name>
<surname>Aigrot</surname> <given-names>MS</given-names>
</name>
<name>
<surname>Williams</surname> <given-names>A</given-names>
</name>
<name>
<surname>Moyon</surname> <given-names>S</given-names>
</name>
<name>
<surname>Tepavcevic</surname> <given-names>V</given-names>
</name>
<name>
<surname>Moutkine</surname> <given-names>I</given-names>
</name>
<etal/>
</person-group>. <article-title>Class 3 semaphorins influence oligodendrocyte precursor recruitment and remyelination in adult central nervous system</article-title>. <source>Brain</source> (<year>2011</year>) <volume>134</volume>:<page-range>1156&#x2013;67</page-range>. doi: <pub-id pub-id-type="doi">10.1093/brain/awr022</pub-id>
</citation>
</ref>
<ref id="B81">
<label>81</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hendrickx</surname> <given-names>DA</given-names>
</name>
<name>
<surname>Koning</surname> <given-names>N</given-names>
</name>
<name>
<surname>Schuurman</surname> <given-names>KG</given-names>
</name>
<name>
<surname>van Strien</surname> <given-names>ME</given-names>
</name>
<name>
<surname>van Eden</surname> <given-names>CG</given-names>
</name>
<name>
<surname>Hamann</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Selective upregulation of scavenger receptors in and around demyelinating areas in multiple sclerosis</article-title>. <source>J Neuropathol Exp Neurol</source> (<year>2013</year>) <volume>72</volume>:<page-range>106&#x2013;18</page-range>. doi: <pub-id pub-id-type="doi">10.1097/NEN.0b013e31827fd9e8</pub-id>
</citation>
</ref>
<ref id="B82">
<label>82</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Werneburg</surname> <given-names>S</given-names>
</name>
<name>
<surname>Jung</surname> <given-names>J</given-names>
</name>
<name>
<surname>Kunjamma</surname> <given-names>RB</given-names>
</name>
<name>
<surname>Ha</surname> <given-names>SK</given-names>
</name>
<name>
<surname>Luciano</surname> <given-names>NJ</given-names>
</name>
<name>
<surname>Willis</surname> <given-names>CM</given-names>
</name>
<etal/>
</person-group>. <article-title>Targeted complement inhibition at synapses prevents microglial synaptic engulfment and synapse loss in demyelinating disease</article-title>. <source>Immunity</source> (<year>2020</year>) <volume>52</volume>:<fpage>167</fpage>&#x2013;<lpage>182.e7</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2019.12.004</pub-id>
</citation>
</ref>
<ref id="B83">
<label>83</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fernandez-Castaneda</surname> <given-names>A</given-names>
</name>
<name>
<surname>Chappell</surname> <given-names>MS</given-names>
</name>
<name>
<surname>Rosen</surname> <given-names>DA</given-names>
</name>
<name>
<surname>Seki</surname> <given-names>SM</given-names>
</name>
<name>
<surname>Beiter</surname> <given-names>RM</given-names>
</name>
<name>
<surname>Johanson</surname> <given-names>DM</given-names>
</name>
<etal/>
</person-group>. <article-title>The active contribution of OPCs to neuroinflammation is mediated by LRP1</article-title>. <source>Acta Neuropathol</source> (<year>2020</year>) <volume>139</volume>:<page-range>365&#x2013;82</page-range>. doi: <pub-id pub-id-type="doi">10.1007/s00401-019-02073-1</pub-id>
</citation>
</ref>
<ref id="B84">
<label>84</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giovannoni</surname> <given-names>G</given-names>
</name>
<name>
<surname>Heales</surname> <given-names>SJ</given-names>
</name>
<name>
<surname>Land</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Thompson</surname> <given-names>EJ</given-names>
</name>
</person-group>. <article-title>The potential role of nitric oxide in multiple sclerosis</article-title>. <source>Mult Scler</source> (<year>1998</year>) <volume>4</volume>:<page-range>212&#x2013;6</page-range>. doi: <pub-id pub-id-type="doi">10.1177/135245859800400323</pub-id>
</citation>
</ref>
<ref id="B85">
<label>85</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname> <given-names>MA</given-names>
</name>
<name>
<surname>Palace</surname> <given-names>J</given-names>
</name>
<name>
<surname>Stabler</surname> <given-names>G</given-names>
</name>
<name>
<surname>Ford</surname> <given-names>J</given-names>
</name>
<name>
<surname>Gearing</surname> <given-names>A</given-names>
</name>
<name>
<surname>Miller</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>TIMP-1 and TIMP-2 levels in multiple sclerosis. a longitudinal clinical and MRI study</article-title>. <source>Brain</source> (<year>1999</year>) <volume>122</volume>(<issue>Pt 2</issue>):<page-range>191&#x2013;7</page-range>. doi: <pub-id pub-id-type="doi">10.1093/brain/122.2.191</pub-id>
</citation>
</ref>
<ref id="B86">
<label>86</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Noseworthy</surname> <given-names>JH</given-names>
</name>
<name>
<surname>Lucchinetti</surname> <given-names>C</given-names>
</name>
<name>
<surname>Rodriguez</surname> <given-names>M</given-names>
</name>
<name>
<surname>Weinshenker</surname> <given-names>BG</given-names>
</name>
</person-group>. <article-title>Multiple sclerosis</article-title>. <source>N Engl J Med</source> (<year>2000</year>) <volume>343</volume>:<page-range>938&#x2013;52</page-range>. doi: <pub-id pub-id-type="doi">10.1056/NEJM200009283431307</pub-id>
</citation>
</ref>
<ref id="B87">
<label>87</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hunter</surname> <given-names>SF</given-names>
</name>
<name>
<surname>Weinshenker</surname> <given-names>BG</given-names>
</name>
<name>
<surname>Carter</surname> <given-names>JL</given-names>
</name>
<name>
<surname>Noseworthy</surname> <given-names>JH</given-names>
</name>
</person-group>. <article-title>Rational clinical immunotherapy for multiple sclerosis</article-title>. <source>Mayo Clin Proc</source> (<year>1997</year>) <volume>72</volume>:<page-range>765&#x2013;80</page-range>. doi: <pub-id pub-id-type="doi">10.1016/S0025-6196(11)63598-2</pub-id>
</citation>
</ref>
<ref id="B88">
<label>88</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martin</surname> <given-names>R</given-names>
</name>
<name>
<surname>McFarland</surname> <given-names>HF</given-names>
</name>
<name>
<surname>McFarlin</surname> <given-names>DE</given-names>
</name>
</person-group>. <article-title>Immunological aspects of demyelinating diseases</article-title>. <source>Annu Rev Immunol</source> (<year>1992</year>) <volume>10</volume>:<page-range>153&#x2013;87</page-range>. doi: <pub-id pub-id-type="doi">10.1146/annurev.iy.10.040192.001101</pub-id>
</citation>
</ref>
<ref id="B89">
<label>89</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Knox</surname> <given-names>KK</given-names>
</name>
<name>
<surname>Brewer</surname> <given-names>JH</given-names>
</name>
<name>
<surname>Henry</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Harrington</surname> <given-names>DJ</given-names>
</name>
<name>
<surname>Carrigan</surname> <given-names>DR</given-names>
</name>
</person-group>. <article-title>Human herpesvirus 6 and multiple sclerosis: Systemic active infections in patients with early disease</article-title>. <source>Clin Infect Dis</source> (<year>2000</year>) <volume>31</volume>:<fpage>894</fpage>&#x2013;<lpage>903</lpage>. doi: <pub-id pub-id-type="doi">10.1086/318141</pub-id>
</citation>
</ref>
<ref id="B90">
<label>90</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferrante</surname> <given-names>P</given-names>
</name>
<name>
<surname>Mancuso</surname> <given-names>R</given-names>
</name>
<name>
<surname>Pagani</surname> <given-names>E</given-names>
</name>
<name>
<surname>Guerini</surname> <given-names>FR</given-names>
</name>
<name>
<surname>Calvo</surname> <given-names>MG</given-names>
</name>
<name>
<surname>Saresella</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Molecular evidences for a role of HSV-1 in multiple sclerosis clinical acute attack</article-title>. <source>J Neurovirol</source> (<year>2000</year>) <volume>6 Suppl 2</volume>:<page-range>S109&#x2013;14</page-range>.</citation>
</ref>
<ref id="B91">
<label>91</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Daibata</surname> <given-names>M</given-names>
</name>
<name>
<surname>Komatsu</surname> <given-names>T</given-names>
</name>
<name>
<surname>Taguchi</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Human herpesviruses in primary ocular lymphoma</article-title>. <source>Leuk Lymphoma</source> (<year>2000</year>) <volume>37</volume>:<page-range>361&#x2013;5</page-range>. doi: <pub-id pub-id-type="doi">10.3109/10428190009089436</pub-id>
</citation>
</ref>
<ref id="B92">
<label>92</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taus</surname> <given-names>C</given-names>
</name>
<name>
<surname>Pucci</surname> <given-names>E</given-names>
</name>
<name>
<surname>Cartechini</surname> <given-names>E</given-names>
</name>
<name>
<surname>Fie</surname> <given-names>A</given-names>
</name>
<name>
<surname>Giuliani</surname> <given-names>G</given-names>
</name>
<name>
<surname>Clementi</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Absence of HHV-6 and HHV-7 in cerebrospinal fluid in relapsing- remitting multiple sclerosis</article-title>. <source>Acta Neurol Scand</source> (<year>2000</year>) <volume>101</volume>:<page-range>224&#x2013;8</page-range>. doi: <pub-id pub-id-type="doi">10.1034/j.1600-0404.2000.101004224.x</pub-id>
</citation>
</ref>
<ref id="B93">
<label>93</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nicoll</surname> <given-names>JA</given-names>
</name>
<name>
<surname>Kinrade</surname> <given-names>E</given-names>
</name>
<name>
<surname>Love</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>PCR-mediated search for herpes simplex virus DNA in sections of brain from patients with multiple sclerosis and other neurological disorders</article-title>. <source>J Neurol Sci</source> (<year>1992</year>) <volume>113</volume>:<page-range>144&#x2013;51</page-range>. doi: <pub-id pub-id-type="doi">10.1016/0022-510X(92)90242-D</pub-id>
</citation>
</ref>
<ref id="B94">
<label>94</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gold</surname> <given-names>R</given-names>
</name>
<name>
<surname>Linington</surname> <given-names>C</given-names>
</name>
<name>
<surname>Lassmann</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Understanding pathogenesis and therapy of multiple sclerosis <italic>via</italic> animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research</article-title>. <source>Brain</source> (<year>2006</year>) <volume>129</volume>:<page-range>1953&#x2013;71</page-range>. doi: <pub-id pub-id-type="doi">10.1093/brain/awl075</pub-id>
</citation>
</ref>
<ref id="B95">
<label>95</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>t Hart</surname> <given-names>BA</given-names>
</name>
<name>
<surname>Hintzen</surname> <given-names>RQ</given-names>
</name>
<name>
<surname>Laman</surname> <given-names>JD</given-names>
</name>
</person-group>. <article-title>Multiple sclerosis - a response-to-damage model</article-title>. <source>Trends Mol Med</source> (<year>2009</year>) <volume>15</volume>:<page-range>235&#x2013;44</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.molmed.2009.04.001</pub-id>
</citation>
</ref>
<ref id="B96">
<label>96</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ransohoff</surname> <given-names>RM</given-names>
</name>
</person-group>. <article-title>Animal models of multiple sclerosis: The good, the bad and the bottom line</article-title>. <source>Nat Neurosci</source> (<year>2012</year>) <volume>15</volume>:<page-range>1074&#x2013;7</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nn.3168</pub-id>
</citation>
</ref>
<ref id="B97">
<label>97</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>t Hart</surname> <given-names>BA</given-names>
</name>
<name>
<surname>Gran</surname> <given-names>B</given-names>
</name>
<name>
<surname>Weissert</surname> <given-names>R</given-names>
</name>
</person-group>. <article-title>EAE: Imperfect but useful models of multiple sclerosis</article-title>. <source>Trends Mol Med</source> (<year>2011</year>) <volume>17</volume>:<page-range>119&#x2013;25</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.molmed.2010.11.006</pub-id>
</citation>
</ref>
<ref id="B98">
<label>98</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferrante</surname> <given-names>P</given-names>
</name>
<name>
<surname>Omodeo-Zorini</surname> <given-names>E</given-names>
</name>
<name>
<surname>Caldarelli-Stefano</surname> <given-names>R</given-names>
</name>
<name>
<surname>Mediati</surname> <given-names>M</given-names>
</name>
<name>
<surname>Fainardi</surname> <given-names>E</given-names>
</name>
<name>
<surname>Granieri</surname> <given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Detection of JC virus DNA in cerebrospinal fluid from multiple sclerosis patients</article-title>. <source>Mult Scler</source> (<year>1998</year>) <volume>4</volume>:<fpage>49</fpage>&#x2013;<lpage>54</lpage>. doi: <pub-id pub-id-type="doi">10.1177/135245859800400202</pub-id>
</citation>
</ref>
<ref id="B99">
<label>99</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morris</surname> <given-names>MM</given-names>
</name>
<name>
<surname>Dyson</surname> <given-names>H</given-names>
</name>
<name>
<surname>Baker</surname> <given-names>D</given-names>
</name>
<name>
<surname>Harbige</surname> <given-names>LS</given-names>
</name>
<name>
<surname>Fazakerley</surname> <given-names>JK</given-names>
</name>
<name>
<surname>Amor</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Characterization of the cellular and cytokine response in the central nervous system following semliki forest virus infection</article-title>. <source>J Neuroimmunol</source> (<year>1997</year>) <volume>74</volume>:<page-range>185&#x2013;97</page-range>. doi: <pub-id pub-id-type="doi">10.1016/S0165-5728(96)00786-2</pub-id>
</citation>
</ref>
<ref id="B100">
<label>100</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haider</surname> <given-names>S</given-names>
</name>
<name>
<surname>Nafziger</surname> <given-names>D</given-names>
</name>
<name>
<surname>Gutierrez</surname> <given-names>JA</given-names>
</name>
<name>
<surname>Brar</surname> <given-names>I</given-names>
</name>
<name>
<surname>Mateo</surname> <given-names>N</given-names>
</name>
<name>
<surname>Fogle</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Progressive multifocal leukoencephalopathy and idiopathic CD4+lymphocytopenia: A case report and review of reported cases</article-title>. <source>Clin Infect Dis</source> (<year>2000</year>) <volume>31</volume>:<page-range>E20&#x2013;2</page-range>. doi: <pub-id pub-id-type="doi">10.1086/318120</pub-id>
</citation>
</ref>
<ref id="B101">
<label>101</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parsons</surname> <given-names>LM</given-names>
</name>
<name>
<surname>Webb</surname> <given-names>HE</given-names>
</name>
</person-group>. <article-title>Identification of immunoglobulin-containing cells in the central nervous system of the mouse following infection with the demyelinating strain of semliki forest virus</article-title>. <source>Br J Exp Pathol</source> (<year>1989</year>) <volume>70</volume>:<page-range>247&#x2013;55</page-range>.</citation>
</ref>
<ref id="B102">
<label>102</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jacobson</surname> <given-names>S</given-names>
</name>
<name>
<surname>Shida</surname> <given-names>H</given-names>
</name>
<name>
<surname>McFarlin</surname> <given-names>DE</given-names>
</name>
<name>
<surname>Fauci</surname> <given-names>AS</given-names>
</name>
<name>
<surname>Koenig</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease</article-title>. <source>Nature</source> (<year>1990</year>) <volume>348</volume>:<page-range>245&#x2013;8</page-range>. doi: <pub-id pub-id-type="doi">10.1038/348245a0</pub-id>
</citation>
</ref>
<ref id="B103">
<label>103</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haring</surname> <given-names>J</given-names>
</name>
<name>
<surname>Perlman</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Mouse hepatitis virus</article-title>. <source>Curr Opin Microbiol</source> (<year>2001</year>) <volume>4</volume>:<page-range>462&#x2013;6</page-range>. doi: <pub-id pub-id-type="doi">10.1016/S1369-5274(00)00236-8</pub-id>
</citation>
</ref>
<ref id="B104">
<label>104</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miller</surname> <given-names>SD</given-names>
</name>
<name>
<surname>Olson</surname> <given-names>JK</given-names>
</name>
<name>
<surname>Croxford</surname> <given-names>JL</given-names>
</name>
</person-group>. <article-title>Multiple pathways to induction of virus-induced autoimmune demyelination: lessons from theiler&#x2019;s virus infection</article-title>. <source>J Autoimmun</source> (<year>2001</year>) <volume>16</volume>:<page-range>219&#x2013;27</page-range>. doi: <pub-id pub-id-type="doi">10.1006/jaut.2000.0489</pub-id>
</citation>
</ref>
<ref id="B105">
<label>105</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bureau</surname> <given-names>JF</given-names>
</name>
<name>
<surname>Drescher</surname> <given-names>KM</given-names>
</name>
<name>
<surname>Pease</surname> <given-names>LR</given-names>
</name>
<name>
<surname>Vikoren</surname> <given-names>T</given-names>
</name>
<name>
<surname>Delcroix</surname> <given-names>M</given-names>
</name>
<name>
<surname>Zoecklein</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Chromosome 14 contains determinants that regulate susceptibility to theiler&#x2019;s virus-induced demyelination in the mouse</article-title>. <source>Genetics</source> (<year>1998</year>) <volume>148</volume>:<page-range>1941&#x2013;9</page-range>. doi: <pub-id pub-id-type="doi">10.1093/genetics/148.4.1941</pub-id>
</citation>
</ref>
<ref id="B106">
<label>106</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cua</surname> <given-names>DJ</given-names>
</name>
<name>
<surname>Groux</surname> <given-names>H</given-names>
</name>
<name>
<surname>Hinton</surname> <given-names>DR</given-names>
</name>
<name>
<surname>Stohlman</surname> <given-names>SA</given-names>
</name>
<name>
<surname>Coffman</surname> <given-names>RL</given-names>
</name>
</person-group>. <article-title>Transgenic interleukin 10 prevents induction of experimental autoimmune encephalomyelitis</article-title>. <source>J Exp Med</source> (<year>1999</year>) <volume>189</volume>:<page-range>1005&#x2013;10</page-range>. doi: <pub-id pub-id-type="doi">10.1084/jem.189.6.1005</pub-id>
</citation>
</ref>
<ref id="B107">
<label>107</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mott</surname> <given-names>KR</given-names>
</name>
<name>
<surname>Gate</surname> <given-names>D</given-names>
</name>
<name>
<surname>Zandian</surname> <given-names>M</given-names>
</name>
<name>
<surname>Allen</surname> <given-names>SJ</given-names>
</name>
<name>
<surname>Rajasagi</surname> <given-names>NK</given-names>
</name>
<name>
<surname>Van Rooijen</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Macrophage IL-12p70 signaling prevents HSV-1-induced CNS autoimmunity triggered by autoaggressive CD4+ tregs</article-title>. <source>Invest Ophthalmol Vis Sci</source> (<year>2011</year>) <volume>52</volume>:<page-range>2321&#x2013;33</page-range>. doi: <pub-id pub-id-type="doi">10.1167/iovs.10-6536</pub-id>
</citation>
</ref>
<ref id="B108">
<label>108</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mott</surname> <given-names>KR</given-names>
</name>
<name>
<surname>Zandian</surname> <given-names>M</given-names>
</name>
<name>
<surname>Allen</surname> <given-names>SJ</given-names>
</name>
<name>
<surname>Ghiasi</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Role of IL-2 and HSV-1 in CNS demyelination in mice</article-title>. <source>J Virol</source> (<year>2013</year>) <volume>87</volume>:<page-range>12102&#x2013;9</page-range>. doi: <pub-id pub-id-type="doi">10.1128/JVI.02241-13</pub-id>
</citation>
</ref>
<ref id="B109">
<label>109</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zwicky</surname> <given-names>P</given-names>
</name>
<name>
<surname>Unger</surname> <given-names>S</given-names>
</name>
<name>
<surname>Becher</surname> <given-names>B</given-names>
</name>
</person-group>. <article-title>Targeting interleukin-17 in chronic inflammatory disease: A clinical perspective</article-title>. <source>J Exp Med</source> (<year>2020</year>) <volume>217</volume>:<fpage>e20191123</fpage>. doi: <pub-id pub-id-type="doi">10.1084/jem.20191123</pub-id>
</citation>
</ref>
<ref id="B110">
<label>110</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burkett</surname> <given-names>PR</given-names>
</name>
<name>
<surname>Kuchroo</surname> <given-names>VK</given-names>
</name>
</person-group>. <article-title>IL-17 blockade in psoriasis</article-title>. <source>Cell</source> (<year>2016</year>) <volume>167</volume>:<fpage>1669</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2016.11.044</pub-id>
</citation>
</ref>
<ref id="B111">
<label>111</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hirose</surname> <given-names>S</given-names>
</name>
<name>
<surname>Jahani</surname> <given-names>PS</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>S</given-names>
</name>
<name>
<surname>Jaggi</surname> <given-names>U</given-names>
</name>
<name>
<surname>Tormanen</surname> <given-names>K</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Type 2 innate lymphoid cells induce CNS demyelination in an HSV-IL-2 mouse model of multiple sclerosis</article-title>. <source>iScience</source> (<year>2020</year>) <volume>23</volume>:<fpage>101549</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.isci.2020.101549</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>